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1. Introduction 
Head and neck squamous cell carcinoma (HNSCC) encompasses a heterogeneous group of 
malignant tumors that arise in the oral cavity, nasopharynx, oropharynx, larynx, or 
hypopharynx. HNSCC accounts for approximately 90% of head and neck cancers (HNC). More 
than 300,000 new cases of HNSCC and about 150,000 deaths per year were estimated (Ferlay 
et al., 2015). In Germany, roughly 20,000 new cases of HNC with 10,000 deaths were 
registered in 2012, which accounted for about 3.4% of all cancer incidences (Kaatsch et al., 
2017). Although HNSCC represents only a small proportion of the overall cancer incidence, 
the prognosis of patients with HNSCC remains poor, with 5-year overall survival rate of 
40 - 50%. Treatment choice for an early stage HNSCC is either surgery or radiotherapy as a 
single-modality, whereas multimodality treatment is important for treating patients with locally 
advanced HNSCC in stage T3 or T4 (Colevas et al., 2018). Radiotherapy remains an 
indispensable and crucial element for the curative care of HNSCC. Recent developments of 
curative treatment of HNSCC are: a) optimization of fractionation schedules, b) the use of high 
precision radiotherapy modules i.e., proton therapy and intensity-modulated radiation therapy, 
and c) implementation of chemotherapeutics and/or immunotherapeutics in treatment plans 
(Haddad and Shin, 2008; Santuray et al., 2018). One of the major biological factors that 
influences the radiation response of tumors and normal tissues, namely intrinsic radiation 
sensitivity, varies among patients (West et al., 1993). Patients, hence, respond to radiation 
exposure differently. However, patient stratification for treatment planning relies primarily on 
the stage of disease and primary location, whereas intrinsic radiation sensitivity remains, in 
general, unconsidered (Caudell et al., 2017). 
To individually tailor radiotherapy for a patient, a robust predictive assay, by which the radiation 
response of tumors can be determined prior to the onset of treatment, is currently in a great 
need (Baumann et al., 2016). Molecular signatures e.g., tumor hypoxia, cancer stem cell 
expression, glucose uptake rate, gene signatures, and DNA damage response related 
biomarkers demonstrated promising potentials as predictive biomarkers for radiotherapy 
(Yaromina et al., 2012). Gamma H2AX (γH2AX) – a phosphorylated variant of histone H2AX, 
represent DNA double strand breaks (DSB) inflicted by genotoxic agents such as radiation 
(Rogakou et al., 1998). Upon DNA damage induction, accumulation of γH2AX can be 
visualized as foci by antibody-based approaches. The central role of γH2AX in DNA DSB repair 
mechanisms allows γH2AX to be used as a DNA DSB biomarker (Kinner et al., 2008). Residual 
γH2AX foci (24 h post irradiation) indicate unsuccessful repair of DNA DSB, leading to cell 
death (Banáth et al., 2010). Therefore, radiation response can be determined by the 
quantification of residual γH2AX foci. Determination of residual γH2AX foci correlated with 
intrinsic radiation sensitivity of cervical cancer cell lines (Banáth et al., 2004). In in vivo studies, 
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numbers of residual γH2AX foci in irradiated tumor xenograft models demonstrated a distinct 
difference between a radiosensitive and a radioresistant tumor model (Menegakis et al., 2011), 
and correlated negatively with local tumor control values of different hHNSCC xenograft 
models (Koch et al., 2013). Moreover, residual γH2AX foci numbers in ex vivo irradiated 
patient-derived materials were able to classify radiosensitivity based on clinical radiation 
response of the cancers (Menegakis, von Neubeck et al., 2015). Even though the ex vivo 
γH2AX foci assay could potentially be introduced as a predictive assay for clinical trials, several 
technical challenges need to be addressed. A tumor biopsy serves as a representative of the 
corresponding bulk tumor, providing molecular and cellular information of the tumor at a certain 
time point. However, a question concerning the representativeness of a single biopsy in 
relation to the corresponding bulk tumor has arisen due to a high heterogeneous trait of tumors. 
In addition, it is necessary to identify whether radiation response between ex vivo irradiated 
biopsies and the corresponding in vivo irradiated tumors are comparable.  
This study aims to further optimize and develop the ex vivo γH2AX foci assay by: 
1. Investigating the heterogeneity of residual γH2AX foci among equally treated biopsies, 
2. Determining the degree of heterogeneity in the formation and removal of γH2AX foci 
between the in vivo and ex vivo set-up of the assay, and 
3. Investigating the comparability of radiation response determined by γH2AX foci 
between in vivo irradiated tumors and the corresponding ex vivo irradiated biopsies. 
Human head and neck squamous cell carcinoma (hHNSCC) tumor models (SKX, UT-SCC-45, 
FaDu, Cal33, and UT-SCC-5) established in the pathogen-free animal facilities were used in 
this entire study (Experimental center and OncoRay, Faculty of Medicine, Technische 
Universität Dresden). Xenotransplantation was performed on NMRI nude mice that carry an 
autosomal recessive mutation in the FOXn1 gene resulting in T-cell deficiency. The 
experiments were approved by the regulatory authorities, and followed the institutional 
guidelines and the German animal welfare regulations.  
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1.1 Effect of ionizing radiation on cellular level 
Ionizing radiation e.g. photons or protons, a type of radiation that is generally applied in the 
clinics, is identified by its capability to penetrate biological materials resulting in ionization of 
intracellular water and macromolecules. Ionizing radiation generates damages on biological 
molecules by either a) direct energy deposition on the target molecules, or b) indirect ionization 
of surrounding water molecules (radiolysis of water) generating free radicals that further ionize 
the target molecules. The radiolysis of water was comprehensively summarized (Breen and 
Murphy, 1995). In brief, the initial step of radiolysis, ionization of water molecules, generates 
aqueous electron (eaq
- ) and oxygen(1+) dihydride (H2O+) (Eq. 1). Oxygen(1+)dihydride 
subsequently reacts to a water molecule (Eq. 2) forming a hydronium ion (H3O+) and a hydroxyl 
radical (⦁OH). Radiation directly excites water molecules followed by hemolysis into a hydrogen 
radical (⦁H) and a hydroxyl radical (Eq. 3). The presence of hydroxyl radicals can result in the 
production of hydrogen peroxide (H2O2) (Eq.4). In the presence of oxygen, aqueous electron 
reacts to oxygen molecules resulting in superoxide (Eq. 5.), thereby enhancing the effect of 
radiation on biomolecules (Herrmann et al., 2006). 
 H2O 
hν
→  H2O
++ eaq-  (1) 
 H2O
++ H2O → H3O
+ + ⦁OH (2) 
 H2O 
hν
→  ⦁H + ⦁OH (3) 
 ⦁OH + ⦁OH → H2O2 (4) 
 eaq
-  + O2 → ⦁O2 (5) 
Multiple reactive oxygen species produced during the ionization process react with all 
biological macromolecules such as proteins (Kumta and Tappel, 1961), membrane lipids 
(Konings, 1987), and DNA molecules (Schulte-Frohlinde and Bothe, 1991), generating 
damages on these molecules and disrupting their physiological effects. The schematic 
illustration of direct- and indirect damage on DNA induced by ionizing radiation is depicted 
(Figure 1.1). The introduction of ionizing radiation to cells affects multiple cellular and 
physiological functions. To date, the major target of ionizing radiation-induced damages is 
DNA, promoting cell death, mutagenesis, and carcinogenesis. In general, a single dose of 1 Gy 
X-ray irradiation can induce approximately 1000 single strand breaks (SSB) and 20-40 double 
strand break (DSB). Additionally, SSB on both strands in proximity can lead to a formation of 
a DSB. Whereas, adjacent multiple DSB can cause a clustered DNA DSB lesion, for which a 
tedious repair process is required (Oike et al., 2016). Shortly after DNA damage induction, 
cells initiate a defensive mechanism so-called DNA damage repair to rectify the damages.  
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Cells regain their original functions and the ability to reproduce following the complete DNA 
repair. Cells with unrepaired damage(s), however, will undergo one of the cell death 
mechanisms (Kinner et al., 2008). 
1.1.1 Radiation induces cell death 
Radiation-induced cell death can be processed by a number of mechanisms e.g., mitotic 
catastrophe, apoptosis, and necrosis. Mitotic catastrophe is the mode of cell death when 
damage is induced by irradiation or chemotherapeutics. The majority of damaged cells treated 
with therapeutic irradiation dose do not die immediately. Instead, the damaged cells remain 
intact and morphologically active (Herrmann et al., 2006). Subsequently, the damaged cells 
may proceed to mitosis causing an abnormal cell division which generally leads to the 
formation of multi-nucleate giant cells with uncondensed chromosome (Castedo et al., 2004). 
This process occurs probably due to cells entering mitosis with unrepaired or misrepaired 
damages. Following the abnormal mitosis, an insufficiency of critical genetic materials results 
in a deficiency of essential proteins leading to the loss of replicative capacity and cell death, 
thereafter (Vakifahmetoglu et al., 2008). Mitotic catastrophe can, also, serve as an initiator for 
other cell death mechanisms e.g., apoptosis or senescence (Joiner and van der Kogel, 2009). 
 
Figure 1.1 Ionizing radiation induces damages on macromolecules  
Direct damages on DNA and other macromolecules are induced by ionization of the molecules 
and disruption of their chemical bonds. Damages can be indirectly inflicted by ionization of 
surrounding water molecules, which produces free radicals, which in turn cause damages on 
the biomolecules.  
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Apoptosis is a highly regulated process and considered as one of the main cell death 
mechanisms following ionizing radiation exposure. Cell shrinkage, chromatin condensation, 
collapsed cytoplasm, nuclear envelope disassembly, and DNA fragmentation are common 
morphological alterations of cells undergoing apoptosis (Alberts et al., 2002). A family of 
protease, namely caspase, is involved in the intracellular machinery of apoptosis. To initiate 
apoptosis, initiator caspases (Caspase 2, 8, 9, 10) are activated followed by the activation of 
effector caspases (Caspase 3, 6, 7). Apoptosis is initiated via two main pathways: the extrinsic 
or death receptor pathway and the intrinsic or mitochondrial pathway (Elmore, 2007). The 
extrinsic pathway begins with the docking of death ligands e.g., TNF (Tumor necrosis factor), 
FasL (Fas ligand) on their cellular specific receptors e.g., TNFR1 (TNF receptor 1), Fas (Fas 
cell surface death receptor), resulting in the activation of initiator caspase 8 and 10, which 
subsequently triggers the effector caspase 3. In contrast, the intrinsic pathway requires the 
release of mitochondrial proteins e.g., cytochrome-C in order to initiate the process. The 
release of mitochondrial proteins leads to the activation of initiator caspase 9 and subsequently 
the effector caspase 3. Finally, adjacent parenchymal cells, neoplastic cells or macrophages 
execute the end state of apoptosis - phagocytosis of apoptotic cells. (Elmore, 2007). The 
mitochondrial pathway is more relevant to radiation-induced apoptosis since the induction of 
the process is dependent on DNA damages and an increase of p53 expression (Herrmann et 
al., 2006). 
In contrast to apoptotic cell death where the dying process is well regulated and does not 
trigger cytotoxicity, cells that die as a result of acute injury typically swell and burst, resulting 
in the release of cytoplasmic contents to the surrounding area (Alberts et al., 2002). The 
release of cytoplasmic contents generally causes a local inflammatory response. Cell death 
driven by necrosis occurs in cells that are heavily damaged by, for example, irradiation, severe 
changes of physiological conditions e.g., hypoxia, or a lack of ATP synthesis. Necrosis is 
considered as a passive mechanism since the execution of necrosis requires no additional 
protein synthesis and minimal energy. Morphological alteration of necrotic cells is 
characterized by extensive cell swelling, cell membrane disruption, release of cytoplasm, 
endocytosis of plasma membrane, and random DNA degradation (Syntichaki and 
Tavernarakis, 2002). 
Senescence refers to a state of permanent cell cycle arrest where cells are irreversibly 
interrupted in cell propagation (Campisi, 2013). A gradual loss of replicative potential, so-called 
replicative senescence, is associated with aging process and correlates with telomere 
shortening at the end of chromosomes during proliferation. Alternatively, the introduction of 
cellular stresses such as activation of oncogene or DNA damages induced by irradiation can 
drive cells to enter premature senescence (Joiner and van der Kogel, 2009). Senescent cells 
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are limited in cell propagation, cells are, however, intact and metabolically survive with an 
increased expression of senescence-associated β-galactosidase. Although, senescent cells 
are metabolically active, they do not contribute to tumor and tissue survival due to the 
permanently suspended cell progression. The master regulators of senescence are p53 and 
p16INK4a-pRb tumor suppressor pathways (Pawlikowski et al., 2013). Loss of p53 in the vast 
majority of cancers promotes cells to bypass senescence by which increasing cancer cell 
propagation, although a subset of tumors undergoes senescence post irradiation (Schmitt, 
2007). Radiation-induced senescence frequently occurs in fibroblast cells resulting in 
fibrogenesis (Hall and Giaccia, 2012). 
The main purpose of radiotherapy is to diminish cell proliferation and eradicate tumor cells. 
Tumor cells that possess the abilities to form clones (clonogenicity) and maintain the infinite 
cell division capacity are defined as clonogenic cells (Joiner and van der Kogel, 2009). 
Clonogenic cell death is determined by the loss of clonogenicity and infinite reproduction, by 
which tumor cells become non-malignant. The term “clonogenic cell death” caused by 
irradiation covers multiple possible mechanisms (Herrmann et al., 2006). After irradiation, most 
cells attempt to proliferate, thereby, the major cell death mode in clonogenic cell death is mitotic 
catastrophe (mitotic cell death). Alternatively, cells can undergo other cell death mechanisms 
i.e., apoptosis, necrosis, autophagy, or senescence before an onset of mitosis is possible 
(pre-mitotic cell death). Besides the cell death mechanisms, cells can be deactivated (loss of 
original function) by the acceleration of cell differentiation due to radiation exposure, so called 
terminal differentiation. Cell terminal differentiation induced by radiation is frequently observed 
in normal tissues in form of the development of fibrosis, which drastically reduces patients' 
quality of life (Rodemann and Bamberg, 1995; Delanian and Lefaix, 2007). 
1.1.2 Cell-cycle arrest mediated by radiation 
The second countermeasure against radiation-induced DNA damages is the activation of 
cell-cycle checkpoints (Joiner and van der Kogel, 2009). Cells exposed to ionizing radiation 
activate cell cycle progression delays through G1, S, and G2 phases (Bernhard et al., 1995). 
To preserve genetic integrity, damaged cells block the progression through the next phase, 
hence providing additional time for repairing DNA damages. Cell cycle progression is regulated 
by cyclin-dependent kinases (CDK), which become active after associating with their cyclin 
partners. The activation of cell-cycle checkpoints by radiation is a result of cyclin-CDK inhibition 
via either direct inhibition of a cyclin-CDK complex or indirect modulation by dephosphorylation 
of CDK (Joiner and van der Kogel, 2009). The major mediator of G1/S phase transition post 
radiation exposure is p53, which is activated in ATM (ataxia-telangiectasia mutated kinase) 
dependent manner. p53 mediates G1 phase arrest by a transactivation of p21WIF1/CIP1, an 
inhibitor of essential cyclins and CDKs for G1/S phase transition, and GADD45 (growth arrest 
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and DNA damage inducible alpha), a gene mediating growth arrest and DNA damage repair 
(Bernhard et al., 1995). G1 phase arrest induced by irradiation occurs infrequently due to 
mutation of p53 in tumors. Consequently, a loss of functional p53 in a wide range of cancers 
contributes to tumor radioresistance and aggressiveness (McIlwrath et al., 1994). In contrast 
to G1 phase arrest, cells can initiate G2 phase arrest independent of p53 and p21 status in 
response to DNA damage induction (Kastan et al., 1991). Nevertheless, p53 and p21 are 
necessary for sustaining G2 phase arrest after DNA damages (Bunz et al., 1998). In 
radiosensitive cell lines, a longer G2 phase arrest was observed in relation to matched normal 
or radioresistant cell lines (Pawlik and Keyomarsi, 2004). Considering G2 phase arrest in tumor 
cells, the delay might offer a time-extension for repair process by which cell survival after 
sublethal damages is ensured. As such, disruption of G2 phase arrest by inhibitors e.g., 
caffeine or pentoxifylline, induces mitotic catastrophe in irradiated tumor cells resulting in 
radio- and chemo-sensitization effect (Herrmann et al., 2006; On et al., 2011; Filippi-Chiela et 
al., 2013). 
1.2 DNA damage repair 
Within a cell, more than 70,000 endogenous lesions, including 20 DSB, occur daily during 
natural metabolism, serving as a source of spontaneous mutations (Tubbs and Nussenzweig, 
2017). Besides, the exposure of cells to exogenous agents e.g., radiation and chemical agents, 
generates DNA damage. Eukaryotic cells possess a unique DNA repair machinery with a high 
fidelity to counteract endogenous and exogenous DNA damage. DNA DSB is the most lethal 
damage produced by irradiation. Cells utilize predominantly two major mechanisms i.e. 
non-homologous end joining (NHEJ) and homologous recombination (HR) to rectify DNA DSB 
(Willers et al., 2004). A defect in one of the pathways is strongly associated with an extensive 
genomic instability and a high radiosensitivity, particularly in patients suffering from defective 
DNA repair functions (Pollard and Gatti, 2009). Under normoxic condition, cells detect DNA 
DSB through the MRE11-RAD50-NBS1 (MRN) complex, leading to the activation of DNA-PKcs 
(DNA-dependent protein kinase catalytic subunit), ATR (Ataxia telangiectasia and Rad3 
related), and ATM (Bristow and Hill, 2008). Thereafter, ATM or DNA-PKcs phosphorylates 
histone H2AX resulting in the formation of γH2AX in the DSB vicinity. The activation of ATM 
mediated by the MRN complex and the γH2AX formation is regulated in a feedback loop (Uziel 
et al., 2003). DNA damage sensing factors e.g., MDC1 (mediator of DNA damage 
checkpoint 1), and 53BP1 (p53-binding protein 1), and DNA damage repair proteins involved 
in HR and NHEJ are, subsequently, recruited within 1-6 h post radiation exposure (Bristow and 
Hill, 2008). The competition of DNA DSB pathways between NHEJ and HR is partly regulated 
by 53BP1 (p53-binding protein 1) and BRCA1 (breast cancer tumor suppressor protein-1). 
53BP1, an ATM kinase substrate, demotes the end resection mediated by the MRN complex 
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to favor NHEJ. Conversely, BRCA1, a tumor suppressor gene, promotes the end resection 
and removes 53BP1 from DSB to initiate HR in S/G2 phase (Daley and Sung, 2014). 
1.2.1 Non-homologous end joining (NHEJ) 
NHEJ is initiated by the binding of Ku heterodimers (Ku70-Ku80) to both ends of the break 
preventing extensive DNA end resection (Figure 2). Subsequently, Ku heterodimers recruit 
DNA-PKcs to the DSB sites forming the Ku/DNA-PKcs complex. The complex formation 
stimulates the kinase activity of DNA-PKcs and coordinates the repair pathway NHEJ 
(Mladenov et al., 2016). Artemis, an endonuclease, is phosphorylated and recruited to the DSB 
sites by DNA-PKcs. Artemis and Polβ (polymerase β) modify DNA ends, providing compatible 
DNA ends for ligation (Löbrich and Jeggo, 2005). Ligation, the final step of NHEJ that is 
mediated by DNA-PKcs, is carried out by LIG4 (Ligase IV) accompanied with XRCC4 (X-ray 
repair cross complementing 4), XLF (XRCC4-like factor), and PNK (Polynucleotide kinase 3'-
phosphatase). NHEJ is considered as an error-prone mechanism, in which two ends of a DSB 
break are rejoined without the use of homology. This process is a fast process but less 
accurate, thereby causing small deletions or insertions. Despite of the enhanced risk of error, 
gene coding and regulatory regions account only a minimal fraction of the total genome 
(ENCODE Project Consortium, 2012), minimizing the probability of damage occurring in 
protein coding regions. Thereby, the consequence of minor deletions or insertions caused by 
NHEJ are minimal or non-essential (Joiner and van der Kogel, 2009). Moreover, NHEJ is active 
throughout the entire cell cycle providing a flexible repair mechanism that increases the chance 
of survival of damaged cells (Mladenov et al., 2016).  
1.2.2 Homologous recombination (HR) 
In contrast to NHEJ, HR requires sequence homology of sister chromatid serving as a template 
to rejoin broken ends. HR is a slow process (require ca. 6 that occurs in G2/S phase due to 
the requirement of a sister chromatid. However, it provides cells with a highly accurate DSB 
repair mechanism. ATM phosphorylates BRCA1, which is subsequently recruited to DNA DSB 
ends (Figure 2). The MRN complex generates 3'single stranded DNA (ssDNA) overhangs, 
which are immediately coated by RPA (replication protein A). BRCA2 promotes the 
replacement of RPA by RAD51 resulting in nucleoprotein filaments. RAD52 is attracted to 
RAD51-coated nucleoprotein filaments to prevent exonucleolytic degradation. 
RAD51-nucleoprotein filaments invade onto the neighboring sister chromatid leading to the 
formation of a Holliday junction. Finally, Holliday junction is resolved by helicases. Germline or 
somatic mutations of HR repair genes are strongly associated with hereditary and sporadic 
tumorigenesis. For instance, BRCA1/2 mutated genes likely dictate the risk of breast cancer, 
prostate cancer, and ovarian cancer development (Levy-Lahad and Friedman, 2007). 
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Moreover, patients with a hereditary disease such as Fanconi anemia, Bloom disease, and 
Werner disease, which are caused by defects in HR genes, are reported with an extremely 
high radiation sensitivity (Pollard and Gatti, 2009; Krejci et al., 2012). 
 
Figure 1.2 Overview of DNA double strand break (DSB) repair by NHEJ and HR 
Nonhomologous end joining (NHEJ) begins with sensing of DNA ends by Ku heterodimers 
(Ku70 and Ku 80), which subsequently recruit DNA-PKcs. Artemis, an endonuclease recruited 
by DNA-PKcs, and Polβ prepare DNA ends for ligation. The final step of NHEJ is ligation, which 
is conducted by LIG4 with the support of XRCC4, XLF, and PNK. Homologous recombination 
(HR) starts with the resection on DNA breaks to generate single strand DNA (ssDNA) by MRN 
complex. The formation of ssDNA prevents DNA DSB repair via NHEJ, and ssDNA is coated 
by RPA. RPA is replaced by RAD51 with the support of BRCA2. The RAD51 nucleoprotein 
filaments mediate strand invasion on the neighboring sister chromatid leading to the formation 
of Holliday junction. The final step of the process is the resolution of the Holliday junction into 
two DNA duplexes. 
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1.2.3 Base damage repair and single strand break repair 
Base damage repair (BER) and single strand break repair (SSBR) appear to be important for 
ionizing radiation as mutations or defects on the pathways resulting in an increased 
radiosensitivity (Murcia et al., 2003). Depending on the cause of damages, base damage and 
single strand break (SSB), generally, can be repaired by several mechanisms. BER and SSBR 
pathways are relevant for rectifying damages induced by ionizing radiation (Joiner and van der 
Kogel, 2009). About 50 times more SSBs than DSBs are generated by 1 Gy of X-ray irradiation, 
and a great number of endogenous SSBs or base damages occur daily. This implies a strong 
impact of BER and SSBR in maintaining genomic integrity. BER and SSBR pathways are 
illustrated in Figure 3. In brief, BER begins with base damage recognition and removal, which 
are generated by a glycosylase/ DNA lyase. The removal process cut out damaged base 
without removing DNA backbone resulting in an abasic site (sugar residue). The residual DNA 
backbone is subsequently removed by APE1 (apurinic endonuclease 1). In case of multiple 
damaged nucleotides, up to ten nucleotides are removed by APE1. Subsequently, a complex 
of PCNA (proliferating cell nuclear antigen), and DNA polymerases δ and ε synthesizes DNA 
to replace the missing bases. The DNA strand is rejoined by ligase 1 (long patch). A single 
damaged nucleotide, in contrast, is replaced by DNA polymerase β, and completed by DNA 
ligase 3–XRCC1–mediated ligation (short patch) (Joiner and van der Kogel, 2009). Detection 
of SSB is carried out by PARP1 (Poly(ADP-Ribose)-Polymerase 1) with the support of XRCC1. 
SSBR subsequently initiates an additional end-processing step mediated by PNK to shape 
damage ends, resulting in a repair (nicked) intermediate. Thereafter, nucleotide replacement 
via short or long patch process is carried out to complete the repair process. 
Even though SSBs and base damages are unrelated to cell death, unrepaired damages 
occurred during S phase can lead to DSB and genomic instability (Saleh-Gohari et al., 2005). 
In addition, radiation is able to inflict a simple SSB accompanied by a base damages (Nikjoo 
et al., 2001) resulting in a non-DSB clustered damage. In case that radiation-induced SSB are 
located on the opposite side of base damages, processing of damaged bases by BER can 
generate DSB (Lomax et al., 2013). Silencing of PARP1 and XRCC1 in HeLa cells 
considerably increased radiation susceptibility in S phase cells as well as asynchronous cells 
(Godon et al., 2008). Mutation, deletion, and inhibition of PNK, LIG3 or LIG1 can result in 
hyper-radiosensitivity (Webster et al., 1992; Lu et al., 2016). Especially, inhibition of PARP1 
enhances the effectiveness of treatment for BRCA1/BRCA2 deficient tumors, whose HR 
pathway is impaired. This implies a synthetic lethality between HR and BER/SSBR repair 
mechanisms (Joiner and van der Kogel, 2009)
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Figure 1.3 Schematic illustration of base excision repair (BER) and single strand break 
repair (SSBR) pathways 
In BER, glycosylase recognizes and removes different base damages as the first step, 
whereas, PARP and XRCC1 mediate the SSB detection in SSBR. APE1 and PNK 
subsequently generate a repair intermediate for BER and SSBR, respectively. The repair 
intermediate is, thereafter, processed by one of two sub-pathways (short patch or long patch).  
1.2.4 Role of γH2AX in DNA damage repair 
Histone, a family of positively charged proteins, consists of H1, H2A, H2B, H3, and H4. Two 
of each histone form a histone octamer, which wraps DNA double helix forming a nucleosome. 
Histone H2AX, a subtype of the histone H2A family, is a substrate of phosphoinositide 3-
kinase-related protein kinases (PIKKs) such as ATM, ATR, and DNA-PKcs (Podhorecka et al., 
2010). Cellular content of H2AX varies in a wide spectrum, ranging from 2 to 25% depending 
on cell types. Upon DNA DSB induction, histone H2AX becomes phosphorylated (γH2AX) over 
1 - 2 megabases surrounding a DSB end (Rogakou et al., 1998). The phosphorylation of H2AX 
at serine 139 in the SQEY carboxy-terminal tail readily occurs within 1 - 3 min and reaches the 
highest peak at 1 - 2 h post irradiation depending on cell types (Paull et al., 2000). 
Phosphatase 2A (PP2A) or PP2A related enzymes dephosphorylate γH2AX after the complete 
DNA damage repair (Chowdhury et al., 2005; Chowdhury et al., 2008). Residual or persistent 
γH2AX is considered as unrepaired DNA DSB, which potentially induce damaged cells to 
initiate one of the cell death mechanisms (Bonner et al., 2008; Banáth et al., 2010). Gamma 
H2AX plays a central role in DNA DSB repair by recruiting multiple DNA damage repair 
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proteins and retaining those proteins at DNA DSB sites until the damage is successfully 
repaired (Paull et al., 2000; Podhorecka et al., 2010). As such, deficiency in γH2AX and its 
regulators are related to: a) an impaired recruitment of NBS1, BRCA1, and 53BP1 to DNA 
damage sites, b) an increased risk of chromosome aberration and genomic instability, and c) 
an alteration in DNA damage repair capability (Bassing et al., 2002; Celeste et al., 2002; 
Celeste et al., 2003). These lead to an increased radiosensitivity. For instance, SKX, a 
hHNSCC cell line isolated from the floor of the mouth and alveolar bone of a 83-year old 
patient, exhibits an extreme radiosensitivity due to a defect in NHEJ pathway and ATM 
downregulation via miR-421 (Kasten-Pisula et al., 2009; Mansour et al., 2013). Conversely, a 
high expression of endogenous γH2AX in colorectal cancer and non-small cell lung carcinoma 
patients detected by an immunohistological-based method was associated with a poor 
prognosis compared to its counterpart (Matthaios et al., 2012; Lee et al., 2015). It is, therefore, 
suggested that tumors endogenously induce DNA damages to customize their molecular 
mechanisms by which favoring cell proliferation and survival (Tubbs and Nussenzweig, 2017). 
1.3 Prediction of tumor radioresponsiveness 
To achieve a personalized radiotherapy, assessment of radioresponsiveness of the tumor prior 
to the start of radiotherapy is crucial, but it is currently unavailable in the clinics (Baumann et 
al., 2016). It has become evident that radioresponsiveness is strongly correlated with intrinsic 
radiation sensitivity (Deacon et al., 1984; Fertil and Malaise, 1985; Torres-Roca et al., 2005). 
Consequently, a large number of attempts to establish an assay using molecular biomarkers 
and/or omic profile of tumors to predict radiation response for clinical use has been reported 
(West et al., 1993; Vasireddy et al., 2010; La Thangue and Kerr, 2011; Forker et al., 2015; 
Menegakis, von Neubeck et al., 2015; Willers et al., 2015; Eze et al., 2017; Reddig et al., 2018). 
Assessment of DNA damage capacity showed a promising potential in patient classification 
according to intrinsic radiation sensitivity (Willers et al., 2015; Reddig et al., 2018). 
Tumor-omics profiling, as well, provides a substantial information concerning treatment 
response of tumors. Several reports demonstrated that genomic signature of patients were 
associated with treatment responses and overall survival (Torres-Roca et al., 2015; El Naqa 
et al., 2017; Scott et al., 2017). Besides, radiomics exhibit a promising potential for 
personalization of radiotherapy. A predictive model based on over thousands of radiomic 
features extracted from 18F-FDG-PET (Fluorodeoxyglucose positron emission tomography) 
and CT (computed tomography) images showed a high potential in the risk assessment of 
tumor outcomes in HNSCC patients (Vallières et al., 2017). Another study reported a high 
accuracy of 80% in the treatment response prediction by using radiomic features of treatment 
planning CT scans and a machine learning approach in colorectal cancer patients receiving 
chemo-radiotherapy (Bibault et al., 2018).  
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1.3.1 Prediction of tumor radiation sensitivity by γH2AX 
A potential application of γH2AX as a radiosensitivity predictor was firstly reported in a cohort 
of six cervical cancer cell lines (Banáth et al., 2004). The study reported a correlation between 
residual γH2AX level and survival fraction after radiation exposure of 2 Gy, and a difference of 
repair kinetics in a cell line- and p53 status-dependent manner. Clinical applicability of γH2AX 
foci as a marker for treatment response prediction was tested in tumor biopsies from cohorts 
of advanced uterine cervix carcinomas (Bañuelos et al., 2009; Olive et al., 2010). Out of 47 
untreated and eight patients treated with chemo- or radiotherapy, residual γH2AX foci were 
detected; on average, only 25% of tumor nuclei exhibited one or more γH2AX foci 
pre-treatment and 74% after the initiation of treatment (Bañuelos et al., 2009). Out of 26 
patients, 24 ± 19% and 38 ± 19% of cells contained γH2AX foci in biopsies taken before 
treatment and 24 h after exposure to the first fraction of radiotherapy (1.8–2.5 Gy), 
respectively. No correlation between the local tumor control and the fraction of cells that 
retained γH2AX foci was, however, identified (Olive et al., 2010). The studies elicited a 
complexity in the quantification of γH2AX foci in patient materials, for which tumor 
heterogeneity could, probably, be responsible (Cyll et al., 2017).  
Preclinical studies of the γH2AX foci assay as a predictive method for the assessment of tumor 
radiation response in hHNSCC models were reported (Menegakis et al., 2009; Menegakis et 
al., 2011; Koch et al., 2013; Menegakis, von Neubeck et al., 2015). Numbers of residual γH2AX 
foci determined in two hHNSCC cell lines i.e. FaDu and SKX, showed a strong correlation with 
clonogenic cell survival fraction in vitro (r2 > 0.9). In addition, a good correlation between 
observed and predicted survival fraction based on residual γH2AX foci was concluded 
(Menegakis et al., 2009). In hHNSCC subcutaneous xenograft models of FaDu and SKX, 
residual γH2AX foci in a well-perfused area i.e., cells within a distance of 45 µm from the 
nearest vessel, correlated with radiation doses (r2 > 0.75). The slopes of dose response curve 
of residual γH2AX foci could differentiate FaDu and SKX according to their radiation sensitivity 
(Menegakis et al., 2011). In nine hHNSCC tumor xenograft models, a robust negative 
correlation between residual γH2AX foci and the necessary dose to locally control 50% of the 
tumors was reported (Koch et al., 2013). The tumor microenvironment (TME) dependent 
evaluation of γH2AX foci was successfully translated to ex vivo irradiated tumor biopsies and 
patient-derived materials. Residual γH2AX foci quantified in ex vivo irradiated tumor pieces 
were capable of classifying three tumor entities i.e., seminoma, prostate, and glioblastoma 
according to their clinical radiosensitivity (Menegakis, von Neubeck et al., 2015).  
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2 Tumor heterogeneity determined with a γH2AX foci assay: A study in 
human head and neck squamous cell carcinoma (hHNSCC)  
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2.1 Summary of the publication 
Radiation therapy requires a method by which radiosensitivity can be predicted to support 
physicians in planning individualized therapy and improving therapeutic outcomes. Among 
predictive biomarkers, the DNA double strand break marker, γH2AX, is a promising predictor 
of individual radiosensitivity. The clinical relevance of the γH2AX foci assay was demonstrated 
in preclinical studies. Subsequently, a clinically relevant ex vivo set-up of γH2AX foci assay 
based on tumor specimens and biopsies was established. However, the representativeness of 
tumor biopsies for the bulk tumor in the ex vivo γH2AX foci assay need to be validated. The 
aim of this study was to investigate the intra- and intertumoral heterogeneity of residual γH2AX 
foci. In addition, the sample preparation step prior to ex vivo radiation exposure and the foci 
evaluation approach were optimized. Excised tumors of hHNSCC xenograft models with 
different radiosensitivity i.e., SKX, FaDu, and UT-SCC-5, were cut into eight pieces and 
reoxygenated in culture medium for a) 10 h or b) 24 h. Tumor samples were irradiated ex vivo; 
fixed and paraffin embedded 24 h post irradiation. Two consecutive 3 µm sections of the 
central part of the tumor sample were immunostained for a) pimonidazole and BrdU or 
b) γH2AX and DAPI. The foci counting was performed manually in oxic tissue regions. 
The normalized residual γH2AX foci were fitted to a linear mixed-effects model (LMEM). The 
intra- and intertumoral heterogeneity was evaluated on each level of the analysis cascades 
i.e., a) tumor samples of all mice (intramodel), b) tumor samples of a particular mouse 
(intertumoral interspecimen), and c) the microscopic field of views within one tumor sample 
relative to the treatment conditions time and radiation dose (intertumoral intraspecimen). The 
result showed no significant effect of the reoxygenation time (10 h or 24 h) on normalized 
residual γH2AX foci. No intramodel heterogeneity was found exempt in FaDu. In contrast, 
statistically significant intertumoral inter- and intraspecimen heterogeneities were detected in 
all models. This finding indicated a pronounced intertumoral heterogeneity of residual γH2AX 
foci. By applying the newly developed statistic approach, which analyzes the entire factors of 
interest i.e. the γH2AX foci heterogeneity among microscopic fields of view, tumor samples, 
mice, tumor lines, and the treatment conditions simultaneously. The impact of inter- and 
intraspecimen heterogeneity could be differentiated. Thereby, a more reliable statistical 
analysis could be achieved. In a clinical situation, patient-derived tumor biopsies with a greater 
heterogeneity relative to experimental models are expected. Therefore, a comparable or higher 
numbers of randomly selected nuclei from tumor specimens should be evaluated to define 
patient-specific heterogeneity for radiosensitivity prediction. Ideally, analysis on multiple tumor 
specimens that are equally treated under the same ex vivo condition is suggested.  
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3 Heterogeneity of γH2AX foci increases in ex vivo biopsies relative to 
in vivo tumors.  
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3.1 Summary of the publication 
Evaluation of radiation induced γH2AX foci demonstrates a great potential to be developed as 
a predictive assay, by which treatment individualization and improvement of therapeutic 
outcome could be achieved. Tumor heterogeneity, however, poses a significant complexity in 
the determination of tumor radiation response. This study aims to investigate the 
representativeness of a single biopsy and the translatability of ex vivo obtained foci results to 
in vivo tumors. Here, γH2AX foci from two previously published datasets with comparable 
experimental designs exempt sampling and radiation exposure i.e. in vivo and ex vivo, were 
compared. Endogenous (control), initial (30 min post irradiation) and residual foci (24 h post 
irradiation) were corrected, normalized and subjected to LMEM, which fixed- and random 
effects were incorporated in the analyses. In addition, correlation between cellular geometry 
distribution and detected foci was investigated by linear regression. The statistical 
reassessment revealed that radiation and the experimental settings induced alteration in cell 
geometry distribution. In both experimental settings, a slight enlargement of nucleus size after 
radiation exposure was found in most of the analyzed tumor lines. Difference of cell geometry 
distribution was present between in vivo and ex vivo set-up depending on tumor lines. A 
positive linear correlation between detected foci number and nucleus size distribution was 
found in irradiated samples. Significant intratumoural heterogeneity i.e., heterogeneity among 
microscopic field of views within one tumor specimen, was observed in initial γH2AX foci for 
the in vivo set-up in most of evaluated tumor lines. Residual γH2AX foci of the ex vivo set-up 
exhibited a greater degree of intratumoural heterogeneity relative to the in vivo set-up. Solely 
in FaDu, comparable residual γH2AX foci between the experimental settings were found, 
where the sample size of the ex vivo set-up is twice as high as the in vivo set-up. In conclusion, 
the altered cellular geometry distribution of tumor cells post irradiation implies cell-cycle phase 
alterations. The linear relationship between detected foci numbers and nucleus size 
distribution supports the relevance of integrating cellular geometry in data processing by which 
relative foci numbers could be estimated. The greater degree of heterogeneity in γH2AX foci 
for the ex vivo set-up and the difference in nucleus size between the experimental settings 
indicated a strong influence of the culture condition in cellular adaptation and DNA damage 
induction. For an accurate prediction of tumor radiation response based on the ex vivo γH2AX 
foci assay, multiple biopsies per tumor and multiple microscopic field of views per biopsy 
should be accounted in the evaluation. 
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4 Comparable radiation response of ex vivo and in vivo irradiated 
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4.1 Summary of the manuscript 
The clinically relevant ex vivo γH2AX foci assay demonstrates a promising potential as a 
predictive tool for tumor radiation response. Nevertheless, evidence whether biopsies can 
reflect and predict the radiation response of the corresponding bulk tumor is still missing. In 
this study, fine needle biopsies of hHNSCC tumor xenograft models (SKX, FaDu, Cal33, 
UT-SCC-5, UT-SCC-45) were taken prior to a single dose irradiation to the tumor. The biopsies 
were maintained under cell culture condition for 24 h, and subsequently exposed to radiation 
with equivalent doses (0, 2, 4 or 8 Gy). Residual γH2AX foci were evaluated in well-perfused 
regions of in vivo irradiated tumors and ex vivo irradiated biopsies. This experimental design 
provides a possibility to uniquely compare radiation response between both cohorts. Linear 
regression analysis of residual γH2AX foci showed comparable slopes of dose response 
curves (SDRC) of residual γH2AX foci between in vivo irradiated tumors and ex vivo irradiated 
biopsies in four out of five models. In addition, a good degree of comparability in foci numbers 
between ex vivo irradiated biopsies and the corresponding in vivo irradiated tumors was 
observed. To assess the predictive capability of the ex vivo γH2AX foci assay, the slopes were 
compared with the previously reported intrinsic radiation sensitivity (TCD50) of the tumor 
models. The result showed that the SDRC values of residual γH2AX foci were able to 
distinguish between radiosensitive and radioresistant tumor models. In conclusion, ex vivo 
irradiated biopsies can reflect radiation response of in vivo irradiated tumors determined by the 
γH2AX foci assay, with the exception of FaDu tumors. SDRC value might be used as a 
predictor for radiation response in the clinics. The outcome of this study, however, remains to 
be validated in (pre-) clinical studies with a larger cohort. To further enhance the prediction 
accuracy, refinement of the assay by incorporating additional biomarkers would be necessary.  
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Abstract 
Purpose: a) To investigate if an ex vivo cultured and irradiated tumor biopsy reflects and 
predicts the radiation response of the corresponding in vivo irradiated tumor measured with 
the DNA double strand break marker γH2AX foci.  
Materials and methods: Five human head and neck squamous cell carcinoma (hHNSCC) 
xenograft models were used. Fine needle biopsies were taken from anesthetized tumor-
bearing NMRI nude mice prior to in vivo single dose irradiation (0, 2, 4, or 8 Gy) under ambient 
blood flow. Biopsies were ex vivo reoxygenated and irradiated with equivalent doses. Tumors 
and biopsies were fixed 24 h post irradiation, and γH2AX foci were assessed in oxygenated 
tumor regions.  
Results: Linear regression analysis showed comparable slopes of the residual γH2AX foci 
dose response curves in four out of five hHNSCC models when in vivo and ex vivo cohorts 
were compared. The slopes from ex vivo biopsies and in vivo tumors could classify the 
respective tumor model as sensitive or resistant according to the intrinsic radiation sensitivity 
(TCD50).  
Conclusion: The ability of ex vivo irradiated tumor biopsies to reflect and predict the intrinsic 
radiation response of in vivo tumors increases the translational potential of the ex vivo γH2AX 
foci assay as a diagnostic tool in clinical practice. 
Introduction 
The standard of care for advanced HNSCC comprises surgery followed by 
radio(chemo)therapy or, alternatively, primary radio(chemo)therapy with a total radiation dose 
of ~70 Gy for combined fractionation. Although a routine pathological investigation classifies 
tumor grade and stage prior to initiation of radio(chemo)therapy, the classification generally 
disregards the patient-dependent intrinsic radiosensitivity, which importantly influences 
treatment outcome [1–4]. Thus, a predictive assay that supports physicians to prescribe an 
individualized radiation dose could improve treatment outcome and reduce excess toxicity [1–
7].  
One of the available molecular biomarkers for the determination of intrinsic radiosensitivity is 
the phosphorylated histone H2AX (γH2AX). Phosphorylation occurs within seconds after 
irradiation at serine 139 in vicinity of a DNA double strand break (DSB) [8]. The formed γH2AX 
foci are microscopically detectable and serve as a specific, sensitive, robust, and 
straightforward DNA DSB biomarker [9–14]. GammaH2AX foci demonstrated a promising 
capability in stratifying tumors according to their intrinsic radiosensitivity. Previously, residual 
γH2AX foci (24 h post irradiation) predicted the radiation response of in vivo irradiated 
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hHNSCC xenograft tumors [15,16]. Based on this, a clinical relevant ex vivo γH2AX foci assay 
was established, showing its predictive potential in specimens of established tumor models 
and surgical patient-derived biopsies by grouping them according to the known clinical 
radiosensitivity [17–20]. However, evidence that an ex vivo cultured and irradiated tumor 
biopsy can reflect and predict the radiation response of the corresponding in vivo irradiated 
tumor is still missing. In this study, fine needle biopsies were taken from xenotransplanted 
hHNSCC prior to a single dose irradiation to the tumor. The biopsies were exposed to radiation 
with equivalent doses and γH2AX foci, as a marker of DNA double strand breaks, were 
assessed in both in vivo tumors and ex vivo biopsies. This experimental design allowed for a 
matching comparison of radiation response between the in vivo and ex vivo scenario. The 
experimental tumor models were categorized according to the slopes of the dose-response 
curves (SDRC) of residual γH2AX foci, a potential radiation sensitivity predictor [15,18,19], and 
their radiation sensitivity based on previously determined data [15,16,21] to assess the 
prediction capability of the ex vivo assay.  
Materials and Methods 
Animal and experimental tumor models 
Five established hHNSCC lines i.e., SKX, FaDu, Cal33, UT-SCC-5, and UT-SCC-45 were 
investigated. Characteristics of these tumor models [15,22,23] as well as their 
xenotransplantation were previously described [15,21,24]. In brief, 7 - 14 weeks old male and 
female NMRI (nu/nu) mice from the pathogen-free animal breeding facilities (Experimental 
Center and OncoRay, Faculty of Medicine, Technische Universität Dresden, Germany) were 
whole body irradiated with 4 Gy 2 - 5 days prior to transplantation (X-rays, Maxishot 200 
Y.TU/320-D03, Yxlon Int., Hamburg, Germany; 200 kV, 20 mA; 0.5 mm Cu filter; dose rate 
1 Gy/min). Small pieces of a source tumor were subcutaneously transplanted on the hind-leg 
of anesthetized mice (Ketamine ([Ketamin 500 Curamed®, Curamed Pharma, Karlsruhe, 
Germany] 100 mg/kg) and Xylazine ([Rompun®, Bayer Healthcare, Leverkusen, Germany] 
10 mg/kg)). Microsatellite, histology, and volume doubling times were assessed for validation 
of tumor lines. The animal facilities and the experiments were approved by the regulatory 
authorities and followed the institutional guidelines as well as the German animal welfare 
regulations. 
In vivo and ex vivo experimental settings 
Figure 1 summarizes the workflow of the in vivo and ex vivo procedures. Animals bearing 
tumors with a maximum diameter of ~10x10 mm (~1 cm2) were anesthetized and randomly 
allocated to the treatment arms. Fine needle biopsies (BioPince 18G, 1.3 mm, Angiotech-
Medical Device Technologies Inc., Gainesville, USA) were taken. Tumor biopsies were 
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immediately transferred into petri dishes coated with 1.5% agarose (A9539, Sigma–Aldrich, 
Taufkirchen, Germany)). Biopsies were maintained in 2.5 ml Dulbecco’s MEM culture medium 
supplemented with 2% HEPES, 1% Na pyruvate, 1% non-essential amino acids, 1% penicillin 
streptomycin (all Biochrom, Berlin, Germany); and 10% FCS (Sigma-Aldrich, Taufkirchen, 
Germany) at 37°C and 5% CO2.  
In vivo irradiation: After recovery from anesthesia, animals were intraperitoneally injected with 
0.1 mg/g body weight pimonidazole (hypoxia marker; Natural Pharmacia International, 
Belmont, MA, USA) and 3.75 mg bromodeoxyuridine (BrdU; proliferation marker; SERVA 
electrophoresis, Heidelberg, Germany) 1 h prior to irradiation. Tumor-bearing legs were locally 
irradiated with single doses of 0, 2, 4, or 8 Gy of X-rays under ambient blood flow. Animals 
were sacrificed 24 h post irradiation. Tumors and the overlying skin were excised; sebaceous 
glands served as positive controls for pimonidazole incorporation. Tumors were fixed in 4% 
formalin and embedded in paraffin. 
Ex vivo irradiation: tumor biopsies were incubated for 20 h prior to media supplementation and 
4 h incubation with 8.5 µmol pimonidazole and 5 µmol BrdU. Four biopsies from SKX, FaDu, 
and UT-SCC-5 tumors were ex vivo exposed to single doses of 0, 2, 4, or 8 Gy (one dose/ 
biopsy). Due to experimental complications e.g., high necrotic fraction and low numbers of 
viable cells within a biopsy, using two biopsies per dose per tumor was more applicable for 
γH2AX foci evaluation. Therefore, two biopsies from Cal33 and UT-SCC-45 tumors received 
the corresponding dose of the in vivo tumor. Immediately after radiation exposure, culture 
medium was exchanged to remove excess pimonidazole and BrdU. Tumor biopsies were fixed 
in 4% formalin and embedded in paraffin 24 h post radiation exposure.  
Staining, imaging acquisition, and γH2AX evaluation 
The immunohistochemical and immunofluorescence staining procedures were previously 
described [15–17,20]. In brief, two consecutive 3 µm sections of the central part of tumors or 
biopsies were stained for a) immunohistochemistry (IHC): pimonidazole (Hypoxyprobe, 
Burlington, MA, USA), BrdU (Agilent Technologies, clone Bu20a, Hamburg, Germany), and 
counterstained with hematoxylin; or b) immunofluorescence (IF): γH2AX at serine 139 (Merck 
Millipore, Upstate, clone JBW301, Darmstadt, Germany) and counterstained with 4’,6-
diamidino-2-phenylindole (DAPI; Invitrogen, Karlsruhe, Germany). ARKTM Kit (Animal 
Research Kit; Agilent Technologies Deutschland, Hamburg, Germany) and Tyramide Signal 
Amplification (TSA) Kits #2 (Alexa 488, Life Technologies, Darmstadt, Germany) were applied 
for IHC and IF, respectively. Image acquisition for IHC and IF was carried out by a fluorescence 
microscope (Axio Imager M1) equipped with dual cameras (digital color camera: 
Axiocam MRc, monochrome camera: AxioCam MRm; Carl Zeiss Jena, Jena, Germany) and a 
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motorized scanning stage (Maerzhaeuser Wetzlar, Wetzlar, Germany). The microscope was 
controlled by the AxioVison 4.9 software (Carl Zeiss Jena, Jena, Germany). IHC stained 
sections were scanned with a magnification of 100X using the digital color camera. 
Subsequently, ten (in vivo) regions of interest (ROI) were selected for IF image acquisition. 
Due to the characteristic of xenograft tumors in which the core of the tumor is highly necrotic, 
and viable tumor cells are located at the growing outer cell layers, biopsy taken from xenograft 
tumors contained a low number of analyzable cells located at each end of the biopsy. As a 
result, five to seven ROIs/ biopsy (ex vivo) could be evaluated. The criteria for the ROI selection 
were as follows; (a) in vivo: a single mouse blood vessel surrounded by multiple BrdU positive 
but pimonidazole negative (oxic) cells; (b) ex vivo: tissue at the outer rim of the biopsy with 
multiple BrdU positive but pimonidazole negative (oxic) cells. For each ROI, a focus stack 
image (17 individual images with a focus interval of 0.25 µm) at 400X magnification was 
acquired. All focal planes of the stack image were calculated to a single extended depth of 
focus image for γH2AX foci evaluation. Within each ROI, oxic cells (in vivo: ≤ 45 µm from 
vessel) with intact nuclei were numbered for randomization and five to ten (in vivo) or ten 
(ex vivo) of these nuclei were randomly selected for foci determination. Manual and blinded 
evaluation of residual γH2AX foci and nuclear area was carried out. Necrotic, apoptotic, 
S-phase, and differentiated cells were excluded from analysis. Supplement figure 1 shows 
exemplary images for IHC and IF staining with annotations for foci analysis. Supplement 
table 1 provides information on total and analyzed numbers of tumors, biopsies and nuclei. 
Data processing and statistical analysis 
As the nucleus area of the randomly selected nuclei is not homogenously distributed, data 
were corrected for the nucleus area [15–17,20,25]. Residual corrected foci of an individual 
nucleus ( ) was calculated by multiplying residual γH2AX foci numbers of an individual 
nucleus ( ) with the quotient of the mean nucleus area of the corresponding tumor or biopsy 
( ) and the area of the individual nucleus ( ) (Eq. 1). 
 
= ×  (1) 
Residual normalized foci of an individual nucleus ( ) from an exposed sample were 
calculated by subtracting  from the exposed sample with a mean cfoci of the unexposed 
tumors or biopsies ( ) (Eq. 2). Negative  were set to zero under the assumption of 
no negative irradiation induced foci.  
 = −  (2) 
Statistical analysis was performed with SPSS 23 (IBM Deutschland, Ehningen, Germany). 
Graphs were plotted with GraphPad Prism 7 (GraphPad Software, San Diego, CA, USA).  
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A mean residual cfoci or nfoci per tumor and biopsy was calculated. The correlation of the 
mean residual cfoci or nfoci and the radiation doses was determined by linear regression 
analysis. Analysis of covariance (ANCOVA) was applied to compare the regression slopes and 
constants (estimated endogenous foci - offsets). The regression slopes and offsets were 
plotted against previously reported local tumor control data [15,16,21] after single 
(TCD50(SDambient)) or fractionated (30 fractions, 6 weeks; TCD50(30fx/ 6weeks)) radiation exposure 
under ambient blood flow. The comparability between the procedures was assessed by 
Bland-Altman analysis. The threshold for statistical significance was defined as P < 0.05. 
Results  
The characteristics of analyzed samples of tumors (in vivo) and biopsies (ex vivo) were 
summarized in supplement table 1. Due to predominant necrotic tissue or tumor cell 
differentiation, analyzable tumors and biopsies ranged between 42.5% (SKX) - 94.4% (Cal33) 
for the in vivo cohort as well as 50.7% (SKX) - 88.9% (Cal33, UT-SCC-45) for the ex vivo 
cohort, respectively. Beside the variations in usable samples, tumor cell density in ROI 
influenced the total analyzable nuclei ranging in vivo from 5,571 (SKX) - 18,790 (Cal33) nuclei 
and ex vivo from 9,851 (SKX) - 37,876 (UT-SCC-5) nuclei. However, equal or lower amounts 
of analyzable cell nuclei could be found in ex vivo biopsies relative to in vivo tumors. 
Supplement figure 1 shows representative images of in vivo tumors and ex vivo biopsies. The 
latter showing BrdU positive cells in the outer, oxic tissue rim and a central hypoxic tissue core 
while in vivo, BrdU positive and oxic cells surround the vessels similar to previous reports 
[15,17,20].  
We investigated whether residual γH2AX foci determined in ex vivo irradiated biopsies can 
reflect radiation response of in vivo irradiated tumors. Comparison of residual cfoci between 
tumors and the corresponding biopsies exposed to equivalent doses were analyzed. In all 
tumor models, a good degree of comparability was observed as indicated by Bland-Altman 
analysis (Suppl. Fig. 2). A dose dependent linear increase of residual γH2AX cfoci and nfoci 
was observed in most of tumor models following in vivo and ex vivo radiation exposure, exempt 
residual cfoci of ex vivo irradiated UT-SCC-5. (cfoci: Suppl Fig 3; Suppl. Table 2; nfoci Fig. 2, 
Table 1).  
The slopes of does response curves (SDRC) of residual nfoci ranged from 0.38 (FaDu) - 1.50 
(UT-SCC-45) for in vivo irradiated tumors, and from 0.19 (FaDu) - 1.48 (UT-SCC-45) for ex vivo 
irradiated biopsies. With the exemption of FaDu, no statistical difference between the slopes 
of the in vivo and ex vivo cohort could be found (Table 1). Ex vivo irradiated FaDu biopsies 
exhibited a significant, ~2-fold lower dose response compared to in vivo irradiated tumors 
(slope of in vivo/ex vivo; P < 0.0001). A similar result was observed in the regression slopes of 
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residual cfoci except for a significant difference in the offsets of dose response curves (ODRC) 
between in vivo and ex vivo cohorts of UT-SCC-45 (Suppl. Table 2).  
As previously reported, SDRC of residual nfoci could potentially be used as a radiation 
response predictor [17]. The SDRC were plotted against the dose needed to control 50% of 
in vivo irradiated tumors locally i.e., TCD50, following fractionated (TCD50(30fx/6weeks), Fig. 3A) or 
single dose irradiation (TCD50(SDambient), Fig. 3B). A range of possible cut-off values for the 
SDRC (0.55 – 0.7) was determined as it discriminates the tumor models for both TCD50 values 
in a resistant and a sensitive population. Moreover, tumor models with a TCD50(30fx/6weeks) above 
the clinical standard dose for primary radiotherapy of ~70 Gy showed lower SDRC (≤ 0.55; 
UT-SCC-5, Cal33, FaDu) while tumor models with lower TCD50(30fx/6weeks) exhibit higher SDRC 
(≥ 0.7). In contrast, SDRC and ODRC of residual cfoci demonstrated an insufficient potential 
in the differentiation of radiosensitivity (Suppl. Fig 4). 
Discussion 
This study is aiming to further enhance the relevance and to translate the γH2AX foci assay 
as a clinically predictive tool for determining intrinsic radiation sensitivity in tumors. Depending 
on their intrinsic radiosensitivity, the response to radiation among patients varies considerably 
[1–7]. Applying a patient-individualized dose based on molecular determinants, omics data, 
and mathematical modelling could offer an improvement of therapeutic outcomes and an 
alleviation of normal tissue toxicity [1,4–6,11,14,26,27]. Among molecular-biomarker based 
assays for the determination of radiation response, the γH2AX foci assay holds a promising 
potential to become a predictive biomarker in clinical practice [14,16–20,25]. However, it is 
currently unclear whether γH2AX foci determined in biopsies can reflect and predict the 
radiation response of the corresponding bulk tumor [14,20,25]. Here, of five hHNSCC models 
with known radiosensitivity, residual γH2AX foci in irradiated tumors in vivo and the 
corresponding biopsies taken from untreated tumors and irradiated ex vivo were evaluated. 
Radiation response was determined by SDRC of residual γH2AX foci. To assess the predictive 
value of the assay, the slopes were compared with the previously reported tumor 
radiosensitivity (TCD50) data [15,16,21]. 
In previous studies, SDRC of residual γH2AX foci demonstrated predictive potential for 
stratifying experimental tumors and patient-derived tumors based on clinically known intrinsic 
radiosensitivity tumors [17–19]. However, those studies exclusively assessed radiation 
induced residual γH2AX foci following ex vivo exposure. To our knowledge, this is the first 
study showing a matching comparison of radiation-induced residual γH2AX foci between 
locally irradiated tumor xenografts (in vivo) and tumor biopsies (ex vivo) taken from xenograft 
tumors prior to radiation exposure. The result demonstrates comparable SDRC of residual 
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nfoci and cfoci of the in vivo irradiated tumors and the ex vivo irradiated biopsies in four out of 
five tumor models. The SDRC values of residual γH2AX nfoci were able to distinguish between 
radioresistant and radiosensitive models. Generally, a total dose up to 70 Gy is applied in 
primary radio(chemo)therapy for head and neck cancer (HNC) [28]. Of note, all the evaluated 
radioresistant tumor models (UT-SCC-5, Cal33, and FaDu) have a fractionated TCD50 value 
higher than the conventional therapeutic dose of 70 Gy. Moreover, the radioresistant tumor 
models showed that the SDRCs of residual γH2AX nfoci were lower than the proposed cut-off 
range of 0.55 – 0.7, while the SDRCs of the radiosensitive tumor models (UT-SCC-45 and 
SKX) were higher than the proposed range. Therefore, a SDRC value might be a suitable 
indicator for discriminating radiosensitive and radioresistant tumors in the clinics. This is in line 
with a recent study on HNC patient-derived biopsies reported a similar cut-off of 0.7 for SDRC 
of residual nfoci [29]. An investigation on additional hHNSCC tumor models and 
patient-derived materials is ongoing to verify the proposed cut-off range.  
The human papillomavirus (HPV) infection status has been shown to be a significant 
prognostic marker for radiation response of HNSCC. HPV positive HNSCC patients 
demonstrated a favorable prognosis [30–34] and HPV positive HNC cells are more highly 
susceptible to radiation compared to HPV negative HNC cells [35,36]. In this study, offsets of 
dose response curves (ODRC) of residual γH2AX foci did not correlate with the radiation 
response of the tumor models (Suppl. Fig 4). The HPV negative, and due to a defective DNA 
damage machinery [23,37], highly radiosensitive model SKX showed a low endogenous 
γH2AX foci number [16] and low ODRC in the both cohorts. In contrast, the HPV positive 
UT-SCC-45 model demonstrated an increased radiosensitivity and a high number of 
endogenous foci [16], which is possibly related to the replication process of HPV. DNA damage 
proteins including γH2AX, 53BP1 and others are activated and recruited to HPV replication 
sites to promote viral genome amplification and stability [38,39].  
Tumor heterogeneity is among the cellular complexities that greatly encumbers the translation 
of molecular biomarkers to the clinics [40,41]. In our previous report, a high intratumoral 
heterogeneity of residual γH2AX foci was detected in hHNSCC models (UT-SCC-5, FaDu, 
SKX) [20]. Likewise, intratumoral heterogeneity in residual γH2AX foci was more pronounced 
as compared to intertumoral heterogeneity (data not shown). In line with our previous report, 
the intra- and intertumoral heterogeneity in the γH2AX foci assay was more pronounced in the 
ex vivo irradiated biopsies than in the in vivo irradiated tumors, which probably contributes to 
the significant difference in the SDRC of residual nfoci and cfoci between the FaDu cohorts 
[20,25]. 
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Despite the high sensitivity of the γH2AX foci assay, its quantification is labor-intensive and 
observer-dependent [14]. (Semi-) automated foci counting algorithms [13,42–44] or 
commercialized software [12,45,46] were implemented in basic- and translational researches. 
Those algorithms and software are, however, currently unsuitable for tissue specimens due to 
complex morphological organization of tumor tissues e.g., cells overlap, varying cell types, and 
complex micromilieu. The evolution of artificial intelligence (AI) has permitted researchers to 
apply machine learning techniques in microscopy [47], radiology [48], detection of melanomas 
[49] as well as outcome prediction in colorectal cancer based on recognition of tissue patterns 
[50]. The advance of AI technology might enable us to overcome the technical challenges in 
cell and foci recognition process. This could pave the way for the development of a non-biased, 
reliable automatic foci-counter for solid tissue specimens therewith the assay could potentially 
be translated, standardized, and implemented as a clinical application in precision radiotherapy 
[11,14].  
In conclusion, with the exception of FaDu tumors, ex vivo irradiated biopsies reflected radiation 
response of in vivo irradiated tumors determined by the γH2AX foci assay. Comparable 
outcomes in γH2AX foci as well as the slopes of dose response curves of residual γH2AX nfoci 
and cfoci between in vivo and ex vivo cohorts were observed. Moreover, the SDRC of residual 
γH2AX nfoci were capable of differentiating radiosensitive and radioresistant tumors based on 
their intrinsic radioresponsiveness. The outcome of this study needs to be validated in (pre-) 
clinical studies with a larger cohort. For further classification into more radiation response 
groups, refinement of the assay by modelling with further biomarkers would be necessary. 
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Fig. 1. Overview of the experimental workflow and γH2AX foci analysis procedures  
In vivo: after recovery from anesthesia, mice were injected with pimonidazole and BrdU 1 h 
prior to a single dose radiation exposure with 0, 2, 4, or 8 Gy. Ex vivo: Four biopsies from 
anesthetized mice bearing SKX, FaDu, and UT-SCC-5 tumors were taken and each biopsy 
was ex vivo exposed to a single dose irradiation of 0, 2, 4, or 8 Gy (one biopsy/ dose). Due to 
experimental complications e.g., high necrotic fraction and low numbers of viable cells within 
a biopsy, the experimental protocol was adapted for Cal33 and UT-SCC-45. Here two biopsies 
per tumors were taken and exposed to a single dose irradiation corresponding to the dose 
applied for the in vivo tumor. Tumors and biopsies were fixed in formalin and embedded in 
paraffin. Gamma H2AX foci were enumerated and analyzed. (IHC: Immunohistochemistry, IF: 
Immunofluorescence, FFPE: Formalin-Fixed Paraffin-Embedded) 
 
Fig. 2. Dose response curves of residual γH2AX nfoci of in vivo irradiated tumors and 
ex vivo irradiated biopsies.  
Linear regression analysis of residual γH2AX nfoci (24 h post irradiation) as a function of 
radiation dose was performed across five hHNSCC tumor models. Symbols (open circle: 
in vivo; open triangle: ex vivo) and error bars represent mean nfoci and standard error of mean 
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(SEM), respectively. The regression constant was adjusted to zero. ANCOVA was applied to 
compare between the slopes of the dose response curves of irradiated tumors and irradiated 
biopsies for each tumor model (Table 1). 
 
Fig. 3. Classification of radiation sensitivity based on tumor control dose 50% (TCD50) 
and slope of dose response curve (SDRC) of residual γH2AX nfoci 
TCD50(30fx/6weeks) (A) or TCD50(SDambient) (B) and slopes of the residual γH2AX nfoci dose response 
curves of the in vivo (open circle) and ex vivo (open triangle) cohort were plotted. The TCD50 
values were previously published [15,16,21]. Error bars represent 95% confidence intervals 
(95% CI) and standard errors (SE) for TCD50 values and the SDRC, respectively. The vertical 
dotted lines at SDRC = 0.55 and 0.7 represent a possible range of the SDRC for the 
classification between resistant and sensitive tumors. The horizontal dotted line represents the 
conventional clinical radiation dose (CRD = 70 Gy) for head and neck cancer treatment. Note: 
Different scaling on y-axis, TCD50(12fx/6weeks) was used for SKX due to its high radiosensitivity. 
Table 1. Linear regression analysis of residual γH2AX nfoci dose response of in vivo irradiated 
tumors and ex vivo irradiated biopsies from five hHNSCC models. The differences of the slopes 
of the dose response curves (SDRC) between the in vivo irradiated tumors and the ex vivo 
irradiated biopsies for each tumor model were determined by ANCOVA. TCD50 after irradiation 
with single dose under ambient condition (SDambient) and 30 fractions within 6 weeks (30fx/ 6 
weeks) are shown. 
  Resistant Sensitive 
  UT-SCC-5 Cal33 FaDu UT-SCC-45 SKX 
in
 v
iv
o
 Slope [± SE] 0.45 ± 0.07 0.49 ± 0.04 0.38 ± 0.03 1.5 ± 0.10 0.79 ± 0.10 
95% CI 0.31; 0.59 0.42; 0.56 0.31; 0.45 1.31; 1.70 0.58; 1.00 
P value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
ex
 v
iv
o Slope [± SE] 0.40 ± 0.05 0.51 ± 0.03 0.19 ± 0.03 1.48 ± 0.12 0.81 ± 0.06 
95% CI 0.31; 0.50 0.44; 0.58 0.13; 0.24 1.23; 1.72 0.68; 0.94 
P value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
P value (Significance 
between slopes) 
0.649 0.666 <0.001 0.847 0.855 
TCD50 (30fx/ 6 weeks)[16,21] 
[95%CI]  
117.2 
[103; 140] 
105.2 
[90; 141] 
85.2 
[77; 96] 
45.4 
[38; 52] 
11.76 
[11.3; 12.2]a,b 
TCD50 (SDambient)[15,21] 
[95%CI] 
42.7 
[38; 48] 
38.1 
[32; 45] 
38.9 
[35; 44] 
23.3 
[15; 29] 
14.9 
[10.9; 18.9] 
a Standard deviation  
b TCD50 fx values after irradiation with 12 fractions within 6 weeks 
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5 Discussion 
Prediction of tumor radiation response has been considered as an essential approach for 
treatment individualization. The ex vivo γH2AX foci assay possesses a high potential as a 
predictive tool for tumor radiosensitivity (Menegakis, von Neubeck et al., 2015). To improve 
the clinical relevance of the assay, five hHNSCC xenograft models i.e., SKX, UT-SCC-45, 
FaDu, Cal33, and UT-SCC-5, were used in this study. The study focused on 2 aspects: a) 
tumor heterogeneity of γH2AX foci, and b) prediction capability of ex vivo irradiated tumor 
biopsies. To investigate tumor heterogeneity of residual γH2AX foci, multiple equally ex vivo 
treated tumor derived specimens were evaluated for γH2AX foci. Data were subjected to a 
LMEM. The result demonstrated a pronounced heterogeneity in residual γH2AX foci in ex vivo 
irradiated tumor specimens (Rassamegevanon et al., 2017) implying the need of substantial 
amounts of nuclei for γH2AX foci evaluation. The degree of heterogeneity in the ex vivo 
irradiated tumor specimens and the in vivo irradiated tumors were determined by statistically 
re-analysis of two published datasets. In addition, the alteration of cellular geometry distribution 
was investigated. The statistical re-assessment suggested the necessity of multiple biopsies 
for an accurate tumor radiosensitivity prediction since a greater heterogeneity of residual foci 
was observed in the ex vivo cohort relative to the in vivo cohort (Rassamegevanon et al., 
2018). The capability of ex vivo irradiated tumor biopsies to reflect radiation response of the 
corresponding tumor was assessed. Radiation response of tumors estimated in ex vivo 
irradiated biopsies was comparable to the corresponding in vivo irradiated tumor. This finding 
supports the clinical applicability of the ex vivo γH2AX foci assay as a predictive approach for 
individualized radiotherapy.   
5.1 Tumor heterogeneity in γH2AX foci assay 
Phenotypic and genetic heterogeneity in cancer have been considered as one of the hallmarks 
of cancer (Hanahan and Weinberg, 2011). Thereby, evaluation of cellular expression of certain 
biomarkers in a limited number of biopsies frequently fails to represent tumor heterogeneity 
within and among patients (Bedard et al., 2013; Jamal-Hanjani et al., 2015; Cyll et al., 2017; 
Tanaka et al., 2017). Like other available biomarkers for the determination of radiation 
response, the evaluation of γH2AX foci demonstrated a considerable magnitude of 
heterogeneity. Here, residual γH2AX foci of multiple equally treated tumor specimens were 
fitted in LMEM (Rassamegevanon et al., 2017). LMEM accounts multiple fixed- and random 
effects that are generally neglected in classical parametric or non-parametric models, although 
they could statistically affect the assessment (Oberg and Mahoney, 2007; Duricki et al., 2016). 
As a result, radiation effect might be over/ underestimated leading to inaccurate patient 
stratification. Intratumoral heterogeneity either interspecimen (among specimens of a tumor) 
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or intraspecimen (among ROIs of a specimen) significantly contributed to the variations in the 
ex vivo γH2AX foci assay. Intratumoral inter- and intra-specimen were evident in all evaluated 
tumor lines (SKX, FaDu, UT-SCC-5). Two out of three models, exempting FaDu, exhibited an 
insignificant heterogeneous γH2AX foci number in intramodel level (among tumors from a 
model). The outcomes reflected a pronounced intensity of tumor heterogeneity in γH2AX foci, 
implying an insufficient representativeness of a single biopsy. As such, multiple biopsies from 
different lesion sites are needed to capture an accurate molecular picture of a tumor 
(Wentzensen et al., 2015; Tanaka et al., 2017). In a preclinical study on biopsies of prostate 
cancer patients, the ex vivo γH2AX foci assay was afflicted with inter- and intra- patient 
heterogeneity (De-Colle et al., 2017), which is consistent with this study. The complex tumor 
niche in patient-derived materials is likely associated with the high variations in the 
quantification of γH2AX foci (Cassidy et al., 2015; Forker et al., 2015).  
Cell-line derived tumor xenograft (CDTX) models fail to capture clonal heterogeneity because 
of the clonal selection process during serial passaging (Adeegbe and Liu, 2017). Nevertheless, 
CDTX possesses a higher degree of complexity (e.g. tumor microenvironment (TME) and 
vascularization). In contrast, 2-dimensional, 3-dimensional cell culture or ex vivo explant 
models preclude the preservation of TME causing lacks of tumor complexity (Majumder et al., 
2015; Meijer et al., 2017). Statistical reassessment of γH2AX foci by LMEM in ex vivo irradiated 
tumors and in vivo irradiated tumors revealed an intriguing result (Rassamegevanon et al., 
2018). Intratumoral heterogeneity in endogenous and residual γH2AX cfoci or nfoci was not 
significantly presented in the in vivo cohort, exempt a pronounced variation in initial cfoci and 
nfoci (30 min following irradiation). Conversely, cfoci and nfoci of the ex vivo cohort 
demonstrated a greater degree of intratumoral heterogeneity. The results indicate the 
monoclonal character of in vivo irradiated CDTX reflected by homogenous DNA damage repair 
capacity. For the ex vivo cohort, the sample processing steps i.e. tumor dissection and 
reoxygenation in presumably optimal conditions for cell growth, potentially led to an 
asynchronous cellular adaptation. Consequently, the degree of variation in DNA damage repair 
capacity in the ex vivo irradiated tumor biopsies was intensified. Despite multiple ROIs as well 
as a substantial number of randomly selected nuclei, numerous analyzable nuclei per ROI 
were excluded due to practical reasons. Additional specimens and nuclei for foci analysis 
would be required to potentially minimize the variation of γH2AX foci assay in the ex vivo cohort 
or assay set-up.  
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5.2 Alteration of nuclear area post irradiation 
Radiation exposure perturbs cell cycle progression in normal cells (Bernhard et al., 1995) and 
cancer cells (Strasser-Wozak et al., 1998). In tumors with p53 deficiency, G2 phase arrest 
predominantly manifests in radiation exposed cells due to the necessity of p53 in mediating 
G1 phase arrest (Kastan and Bartek, 2004). The p53 status of cell line used in this study is 
showed (Table A.1). Four models possess mutation in p53 while the status of UT-SCC-45 is 
unknown. A statistical reassessment by fitting the nuclear area of (un-) irradiated tumors cells 
to LMEM was carried out (Rassamegevanon et al., 2018). Nuclear area determined by DAPI 
staining in irradiated tumors displayed a greater nuclear area, on average, compared to 
unirradiated tumors regardless of the experimental set-ups i.e., in vivo and ex vivo exposure. 
In cell-cycle dynamics, nuclei in G2-phase possesses the largest nuclear volume due to the 
completion of DNA replication (Umen, 2005; Huber and Gerace, 2007; Maeshima et al., 2011). 
An increase in nuclear area in irradiated tumors supports the assumption that tumor cells 
underwent G2-phase arrest. In addition, differences in means of nuclear area between the 
experimental set-ups were detected. Clearly, alteration of TME to the ex vivo condition affects 
nuclear area distribution independent of radiation treatment. The changes in nuclear area 
suggests that cells adapted to the ex vivo conditions by regulating cell proliferation and 
progression through the cell cycle.  
The γH2AX foci assay relies on visualization foci formation on tumor specimens by immuno-
histopathological approaches. A common limitation of the histo-pathological approach is, 
however, that a three-dimensional tumor is represented in a two-dimensional structure. Cells 
and cell nuclei are sectioned in different anatomical planes depending on tumor positioning 
during embedding, thereby exhibiting different nuclear areas. The deviation of nuclear area is 
predominant in cancers in which an abnormal nuclear size and morphology is a common trait 
(Taira et al., 2012; Edens et al., 2013). In this study, foci numbers increased linearly with 
increasing detected nuclear area in all evaluated tumor lines independent of the experimental 
set-ups (Rassamegevanon et al., 2018). The outcome indicates the dependency of foci 
numbers on measured nuclear area, and highlights the relevance of incorporating measured 
nuclear area in the data analysis (Costes et al., 2006).  
The individual nuclear area and treatment conditions influence the biological read-out of 
γH2AX foci numbers. Therefore, the incorporation of the nuclear area in the data processing 
chain of the assay or a mathematical modeling is crucial. In the γH2AX foci assay, foci numbers 
were corrected by applying an individual nuclear area and a mean of nuclear areas of a tumor 
model or a tumor as a weighting factor and a scaling factor, respectively (Menegakis et al., 
2011; Koch et al., 2013; Menegakis, von Neubeck et al., 2015; Rassamegevanon et al., 2017; 
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Rassamegevanon et al., 2018). Since treatment conditions contribute to the change in nuclear 
area as well as inter- and intrapatient heterogeneity of nuclear area are highly possible, 
normalization of foci numbers on a tumor- and treatment specific mean nucleus area is, 
therefore, a feasible approach for personalized prediction of radiosensitivity 
(Rassamegevanon et al., 2017; Rassamegevanon et al., 2018).  
5.3 Clinical relevance of the γH2AX foci assay 
Monitoring of γH2AX foci is considered as a fast and straightforward approach to determine 
DNA DSB (Willers et al., 2015; Reddig et al., 2018). Moreover, the visualization and the 
quantification of γH2AX foci on formalin-fixed paraffin-embedded tissues (FFPE) require solely 
a conventional IF staining and an epifluorescent microscope. Hence, the simplicity and 
accessibility of the assay underline its clinical applicability. Clinical relevance of the γH2AX foci 
assay was demonstrated. A previous study showed that γH2AX foci formation and removal 
were highly dependent on tumor micromilieu (Menegakis et al., 2011). Initial- and residual 
γH2AX foci in two hHNSCC tumor xenograft models, FaDu and SKX, decreased linearly with 
increasing distance from the nearest perfused vessel. Additionally, a linear dose-dependent 
response to irradiation was solely observed in residual γH2AX foci quantified within the 
perfused area. Thereafter, investigation of γH2AX foci in nine hHNSCC tumor xenograft model 
with known radiation sensitivity was performed (Koch et al., 2013). Residual γH2AX foci of 
in vivo irradiated tumors negatively correlated with the intrinsic radiation sensitivity (TCD50). 
Those studies suggested a high potential of γH2AX foci as a predictor of radioresponsiveness. 
Consequently, an ex vivo set-up of the γH2AX foci assay was, henceforth, established 
(Menegakis, von Neubeck et al., 2015). In the study, experimental tumor specimens and 
patient-derived materials were ex vivo exposed to irradiation. Influence of reoxygenation in a 
cell culture medium (0.5 - 12 h) on DNA damage induction of tumor biopsies and predictive 
capacity of the ex vivo γH2AX foci assay were studied. The result demonstrated that residual 
nfoci of ex vivo irradiated tumor biopsies reached a plateau after 6 h of reoxygenation. The 
slope of the dose response curve (SDRC) of residual γH2AX nfoci was able to differentiate 
between radiosensitive and radioresistant tumor entities, thereby supporting clinical feasibility 
of the ex vivo γH2AX foci assay.  
Following the establishment, the sample processing step of the ex vivo γH2AX foci assay was 
optimized. Previously studied reoxygenation times of tumor specimens prior to irradiation were, 
however, impracticable for clinical routine (Menegakis, von Neubeck et al., 2015). Here, the 
reoxygenation time was extended to 24 h without significant influence on residual γH2AX nfoci 
relative to 10 h in all three evaluated tumor lines i.e. SKX, FaDu and UT-SCC-5 
(Rassamegevanon et al., 2017). Clinical practicability of the ex vivo γH2AX foci assay was 
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greatly enhanced due to the high flexibility of the assay. Furthermore, the comparability of 
radioresponsiveness determined by γH2AX foci assay between in vivo irradiated tumors and 
the corresponding ex vivo irradiated biopsies was investigated. Four out of five tumor models 
showed a comparable SDRC of residual γH2AX nfoci and cfoci. Additionally, SDRC of nfoci 
was able to classify tumors according to their radiation sensitivity. A range of predictive cut-off 
scores of 0.55 - 0.7 for SDRC of residual γH2AX nfoci is proposed since the score was capable 
of distinguishing tumors according to intrinsic radiation sensitivity (Yaromina et al., 2010; 
Menegakis et al., 2011). This range of cut-off values is in good agreement with a recent study 
on HNC patient-derived biopsies reporting a similar cut-off of 0.7 for SDRC of residual nfoci 
(Meneceur et al., 2019). In contrast, the offset of the dose response curve (ODRC) of residual 
cfoci was unable to differentiate tumors based on their radiation sensitivity. HPV burden of 
patients is considered as a promising prognostic biomarker for patients with locally advanced 
HNSCC, in which HPV positive is associated with a better prognosis (Lohaus et al., 2014; 
Lohaus et al., 2015; Linge et al., 2016). UT-SCC-45, a radiosensitive HPV positive tumor 
model, exhibited a greater ODRC relative to SKX, a radiosensitive HPV negative tumor model. 
The replication process of HPV requires the activation and recruitment of DNA damage 
proteins including γH2AX, 53BP1 and others to facilitate viral genome amplification and 
stability (Gautam and Moody, 2016; Spence et al., 2016), implying a potential association with 
the high ODRC of γH2AX foci in HPV positive tumors.  
An investigation on ex vivo irradiated patient-derived materials of ten different tumor entities 
was performed (Menegakis, De Colle et al., 2015). Ranking of SDRC of residual γH2AX foci 
was in a good agreement with the anticipated radioresponsiveness of the different tumor 
entities. The result emphasizes clinical feasibility of the assay, and supports the concept that 
intrinsic radiation sensitivity is associated with radiation response of tumors. In addition, the 
result of the investigation is consistent with this study, in which SDRC demonstrated a 
promising predictive capability. Altogether, the γH2AX foci assay holds a great potential to 
become a clinical decision support method.  
5.4 Technical challenges and limitations of the assay 
One of the main biological functions of γH2AX is recruitment and retention of DNA damage 
repair proteins such as the MRN complex, MDC1, 53BP1, and BRCA1 to DNA DSB sites 
(Podhorecka et al., 2010). Phosphorylated H2AX shares multiple biological functions in 
addition to the canonical function in the DNA damage repair pathway (Turinetto and Giachino, 
2015). In cells undergoing senescence, persistent “DNA damage foci” including γH2AX, 
53BP1, ATM and ATM/ATR substrates were observed without detectable DNA damage 
(Rodier et al., 2009). The authors suggested that “DNA damage foci” in senescent cells do not 
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directly represent DNA damages, but the activation of DNA damage signaling mediated by 
senescence. Without exogenous DNA damage induction, a substantial number of 
phosphorylated H2AX mediated by DNA-PKcs, CHK2 (Tu et al., 2013), and ATM (McManus 
and Hendzel, 2005) was detected in cells undergoing mitosis. An additional function of γH2AX 
in the maintenance of genome integrity was reported (Yu et al., 2006; Mirzayans et al., 2015). 
According to the versatile functions of γH2AX, a γH2AX focus does not necessarily represent 
a single DNA DSB (Lukas et al., 2011; Turinetto and Giachino, 2015). In this study, the 
determination of DNA DSB was restricted to the detection of γH2AX foci dependent on tumor 
micromilieu in FFPE tumor specimens. Gamma H2AX signals that were unrelated to radiation 
induced DNA damages were excluded from analysis by the definition of analyzable tumor cells. 
Apoptotic cells generally show γH2AX pan-nuclear and apoptotic ring staining (Solier and 
Pommier, 2014). Similarly, S-phase showed pan-nuclear staining post DNA damage induction 
(de Feraudy et al., 2010). DAPI staining and the corresponding IHC staining provide additional 
information pertaining to cell cycle. Mitotic, detectable apoptotic and necrotic cells were 
excluded. As a result, the analysis of γH2AX was primarily based on G1/G2-phase cells in this 
experimental setting. (Menegakis et al., 2011; Koch et al., 2013; Rassamegevanon et al., 
2017). The cell segregation approach is, however, unable to rule out DSB unrelated γH2AX 
foci in multiple other scenarios e.g. senescent cells or early apoptotic cells in which γH2AX 
formation is irrelevant in the DNA DSB repair context.  
Since the discovery of γH2AX (Rogakou et al., 1998), the γH2AX foci assay has found its place 
in laboratories, where DNA damage repair is evaluated. The assay possesses a high sensitivity 
and straightforwardness, thereby, enhancing the functionality of the assay in various research 
fields e.g., drug discovery and development (Hopp et al., 2017), biodosimetry (Barnard et al., 
2015), molecular radiobiology (Rieckmann et al., 2013), and translational cancer research 
(Ivashkevich et al., 2012; Koch et al., 2013). Common laboratory devices without special 
requirement can conveniently be used for the γH2AX foci assay. Nevertheless, the high 
variability of γH2AX foci quantification i.e., inter-observer variation needs to be considered. 
Two studies reported distinct differences between numbers of γH2AX foci enumerated by 
different investigators (Menegakis et al., 2011; Koch et al., 2013). FaDu and SKX tumors were 
processed, visualized and detected by identical procedures. However, the percentage 
differences of means of residual γH2AX foci between the studies accounted for approximately 
50% and 80% for FaDu and SKX, respectively. In a multi-laboratories investigation of γH2AX 
foci in irradiated human lymphocytes, an extensive variation among laboratories was found 
regardless of foci scoring methods i.e. manual or automated (Barnard et al., 2015). An 
investigation of γH2AX foci in lymphocytes in four different laboratories based on individual 
protocols showed dramatically varied results; approximately 50% variation among the 
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laboratories (K. Rothkamm et al., 2013). Clearly, the performance of the assay is limited due 
to the lack of standardized procedure and reproducibility. Hence, a standardized protocol, a 
standardized foci scoring method and analysis procedure, as well as a multi-institutional study 
are required to validate and to improve clinical applicability of the assay (Williams et al., 2012).  
Several semi-automated foci counting algorithms are currently available as commercial 
software (Runge et al., 2012; Kai Rothkamm et al., 2013) or open-access platforms (Lapytsko 
et al., 2015; Oeck et al., 2015; Feng et al., 2017). Most of the algorithms are based on image 
transformation, segmentation, and intensity-threshold configuration (Ivashkevich et al., 2011). 
As a result, multiple foci with excessively high or low intensity are excluded from the evaluation. 
However, those foci would be counted in manual evaluation. Moreover, overlapping foci or 
greatly adjacent foci are enumerated as a single focus (Lapytsko et al., 2015). As a result, 
automated foci counters might underestimate cellular response upon treatment. Furthermore, 
the available algorithms applied in either basic- or translational research are restricted to in 
vitro models or liquid biopsies. In such models, the homogenous distribution and uniform 
structure of cells facilitate cell and DNA damage foci recognition. In addition, high-resolution 
images acquired by e.g. confocal microscopy are preferable to obtain a well-correlated result 
between manual and automated counting (Ivashkevich et al., 2011; Lapytsko et al., 2015; Oeck 
et al., 2015; Feng et al., 2017). Despite the technical restrictions, (semi-) automated foci 
counters allow the foci determination in a non-biased and high-throughput fashion, therewith, 
increasing clinical relevance of the γH2AX foci assay. In this study, tumor specimens, which 
present a highly complex morphology, were analyzed. In solid tumors, heterogeneous cell 
nuclear size distribution, overlapping cell nuclei and foci, and complex tumor micromilieu 
hindered the development of a reliably automated foci counter and the applicability of the 
available foci counter algorithms so far. Manual foci quantification, despite the practical 
limitations, currently remains the most feasible approach for the determination of DNA damage 
foci in solid tumors (Willers et al., 2015; De-Colle et al., 2017; Rassamegevanon et al., 2017; 
Rassamegevanon et al., 2018; Reddig et al., 2018).  
The determination of cellular response to treatment by the ex vivo γH2AX foci assay relies on 
solid tumor biopsies (Menegakis, von Neubeck et al., 2015; De-Colle et al., 2017; 
Rassamegevanon et al., 2017; Rassamegevanon et al., 2018). A tissue biopsy is considered 
as the gold standard procedure for cancer diagnosis. However, invasive methods are needed 
to obtain tumor materials, which can be challenging if the tumor is deep-seated e.g. pancreatic 
cancer. Consequently, liquid biopsies are being extensively studied for treatment response 
prediction and cancer early detection (Chaudhuri et al., 2015; Rostami and Bratman, 2017; 
Wyatt et al., 2017) since e.g. blood samples are minimally invasive accessible. Studies using 
patient liquid biopsy for the determination of radiation sensitivity with the γH2AX foci assay 
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were reported. Quantification of γH2AX foci in lymphocytes of patients with colorectal cancer 
elicited a significant potential in identifying patients with high risk of late adverse effect following 
radiotherapy (Kroeber et al., 2015). A retrospective study on lymphocytes from patients with 
prostate cancer demonstrated that γH2AX foci disappearance rate correlated with radiation 
toxicity based on CTCAE 4.0 system (van Oorschot et al., 2017). Similar to a study in patients 
with head and neck cancer, γH2AX foci analysis on lymphocytes suggested a promising 
potential in predicting acute normal tissue complications prior to radiation exposure (Goutham 
et al., 2012). However, the quantification of γH2AX foci in lymphocytes reflects the 
radioresponsiveness of normal tissue following radiation exposure (Vasireddy et al., 2010; 
Palla et al., 2017). The translation of the results to the radioresponsiveness of the tumor is 
questionable. Moreover, a study reported a poorly comparable result on the analysis of genetic 
alterations determined in liquid biopsies by two clinically approved laboratories using a similar 
test. (Torga and Pienta, 2018). As a result, liquid biopsies should not be considered as an 
alternative material for tumor tissue but should rather be used as complementary clinical 
testing (Mino-Kenudson, 2016; Jung and Kirchner, 2018; Ratner, 2018). In summary, the 
necessity of tumor biopsies for radiation response determination is emphasized. An 
individualized predictive model, in which tumor radiosensitivity and risk of normal tissue 
complication are incorporated, might be developed by a simultaneous assessment of radiation 
response in liquid and tissue biopsies.  
5.5 Conclusion and Outlook 
The purpose of the current study was to further develop and optimize the ex vivo γH2AX foci 
assay for a clinical application. The results suggest that the ex vivo γH2AX foci assay 
possesses a promising capability in prediction of radioresponsiveness. The high flexibility in 
the sample pre-treatment step (10 h and 24 h reoxygenation in medium) tremendously 
enhanced clinical relevance of the assay. Importantly, ex vivo irradiated tumor biopsies were 
capable of reflecting radiation response of in vivo irradiated matching tumors in four out of five 
hHNSCC tumor models (exception FaDu). The good concordance between both cohorts 
suggests that quantification of residual γH2AX foci in biopsies can predict radiation response 
of the corresponding tumor. In addition, SDRC of residual γH2AX nfoci could be a potential 
predictor for the radiation sensitivity-based classification of tumors. Based on previously 
published TCD50 values, a range of cut-off scores for the SDRC of 0.55 – 0.7 is proposed as it 
was able to distinguish between radioresistant models and radiosensitive models. 
Nonetheless, the proposed cut-off remains to be validated in larger cohorts of experimental 
models of different tumor entities and patient-derived materials.  
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The determination of radiation response by the ex vivo γH2AX foci assay was primarily 
influenced by intratumoral heterogeneity, causing difficulties in an accurate prediction of tumor 
radiation response. The assessment of intertumoral- and intratumoral heterogeneity in γH2AX 
foci from different experimental set-ups (ex vivo, in vivo) revealed that the degree of 
heterogeneity in the ex vivo cohort was greater relative to the in vivo cohort. These results 
emphasize the need of multi-focal and multi-position analysis for a reliable prediction of tumor 
radiation response via the γH2AX foci assay. Before the onset of radio(chemo-)therapy, tumor 
materials available for the γH2AX foci assay are frequently limited. Consequently, to obtain a 
robust SDRC for the prediction of tumor radiation response, applying a set of, at least, four 
radiation doses with an increment of 4 Gy up to 12 Gy is suggested. This could avoid the 
administration of a dose range that might fails to induce sufficient residual foci number for 
linear regression analysis.  
The emerging era of personalized radiation therapy leads to an urgent need in clinical 
predictive assays to support an individualized dose prescription (Lambin et al., 2013; Baumann 
et al., 2016). Currently, preclinical predictive approaches e.g. mathematical modeling 
(McMahon et al., 2016), omics profiling (Herskind et al., 2016), and molecular biomarker 
expression (Forker et al., 2015) are under extensive development and optimization. The 
ex vivo based γH2AX foci assay, as well, has been extensively studied and optimized to meet 
clinical requirements. To validate the proposed cut-off and to increase clinical applicability of 
the assay, a further investigation of residual γH2AX foci in additional tumor models, patients-
derived tumor tissues, and patient-derived xenografts are requisite. The outcome of residual 
γH2AX foci together with the tumor and the patient’s characteristics e.g., treatment modalities 
and response, tumor size, invasiveness, and prognostic biomarkers, can be incorporated. In 
addition, analysis of DNA and RNA expression of DNA damage repair-related genes in tumors 
and normal tissues present a promising capability in treatment response prediction (Herskind 
et al., 2016; El Naqa et al., 2017; Scott et al., 2017). As a result, a multivariate-based prediction 
model could be developed to maximize precision in the prediction (Kirsch et al., 2018). The 
inconsistency in foci enumeration among observers and laboratories poses complications in 
the translation of the assay (K. Rothkamm et al., 2013). Standardization of the γH2AX foci 
assay i.e., sample preparation, staining procedure, foci visualization, image acquisition, and 
foci enumerating procedure, is required to minimize inter-observer and inter-laboratory 
variations. Considering the limitations of the γH2AX foci assay, a non-biased, automated foci 
counting algorithm that facilitates the foci counting process is of great need. The availability of 
the platform would be of major benefit for clinical translation of the assay (Willers et al., 2015), 
thereby bridging the gap between laboratories and clinics. 
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6 Abstract 
Radiotherapy remains one of the most important treatment modalities for cancer therapy. 
Malignant tumors show an extended spectrum of intrinsic radiation sensitivity even among 
tumors of the same entity or with similar histological features. Predicting intrinsic radiation 
sensitivity might improve treatment outcome and allow individualized treatment. Hence, an 
assay that provides a predictive information of the tumor’s intrinsic radiation sensitivity is of 
great need. Histone H2AX, a histone variant of histone H2A family, is rapidly phosphorylated 
upon DNA double strand break (DSB) induction resulting in gamma H2AX (γH2AX). 
Gamma H2AX accumulates at DNA DSB sites and subsequently recruits DNA damage repair 
factors. Formation of γH2AX is visualized by an immunohistology-based approach and 
detected as foci under an epifluorescent microscope. Gamma H2AX foci represent DNA DSBs, 
while residual γH2AX foci (foci detected 24 h post irradiation) are considered as unrepaired 
damages. In previous studies, the γH2AX foci assay showed a high potential as a predictive 
method for radiosensitivity. This thesis aims to further translate and optimize the ex vivo γH2AX 
foci assay for a clinical applicability.  
In this study, all experiments were performed using human head and neck squamous cell 
carcinoma (hHNSCC) xenograft models. For ex vivo investigations, tumors on the hind legs of 
nude mice were excised and cut into multiple pieces, or fine-needle biopsies of the tumors 
were taken. Tumor biopsies were reoxygenated in culture medium for 10 h or 24 h followed by 
radiation exposure of 0 - 8 Gy. Tumor biopsies were fixed and embedded in paraffin 24 h post 
irradiation. For the γH2AX foci assay under in vivo conditions, tumors-bearing mice were 
irradiated with single doses of 0 - 8 Gy. Tumors were excised, fixed, and paraffin embedded 
24 h post irradiation. Manual quantification of γH2AX foci was performed exclusively in 
perfused areas, which were identified by pimonidazole (hypoxic marker) and BrdU 
(proliferation marker) staining. Foci number was corrected, normalized, and statistically 
analyzed by a linear-mixed effects model (LMEM), linear regression model or analysis of 
covariance.  
To investigate tumor heterogeneity in the ex vivo γH2AX foci assay, γH2AX foci were 
enumerated in four equally treated tumor specimens per group i.e. unirradiated and ex vivo 
irradiated with 4 Gy. Strong intratumoral heterogeneity in γH2AX foci was determined with a 
minor intertumoral heterogeneity. No significant effect of reoxygenation between 10 h or 24 h 
was observed, enhancing clinical practicability of the assay. The effect of experimental settings 
was studied by analyzing data from this study (ex vivo) and from comparable published data 
(in vivo) with LMEM. Radiation-induced nuclear area alteration was detected in some of the 
evaluated tumor models in under both experimental conditions. A greater intra- and 
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intertumoral heterogeneity were observed in the ex vivo set-up compared to the in vivo set-up. 
Radiation response determined by the γH2AX foci assay in ex vivo irradiated biopsies and in 
the corresponding in vivo irradiated tumors was evaluated. Between in vivo and ex vivo, four 
out of five tumor models showed comparable slopes of dose response curves (SDRC) of 
normalized and corrected γH2AX foci. SDRC of normalized γH2AX foci was able to classify 
tumors according to their intrinsic radiation sensitivity (TCD50).  
In conclusion, the ex vivo γH2AX foci assay holds a promising potential for predicting radiation 
sensitivity in solid tumors. The comparable radiation response assessed by γH2AX foci of 
in vivo irradiated tumors and the matching ex vivo irradiated tumor biopsies supports clinical 
applicability of the assay. Using SDRC of γH2AX foci as a predictor of radiosensitivity, 
radioresistant and radiosensitive tumors could be classified. The significant intratumoral 
heterogeneity in the ex vivo γH2AX foci assay suggests a limited representativeness of a single 
biopsy for radiosensitivity prediction. Additionally, the change of tumor microenvironment 
modulated cellular adaptation and DNA damage repair capability. The outcomes suggested 
that a sufficient number of cells, regions of interest, and biopsies are required to obtain a solid 
prediction.  
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7 Zusammenfassung  
Die Strahlentherapie ist eine der wichtigsten Behandlungsmethoden für die Krebstherapie. 
Maligne Tumore zeigen ein großes Spektrum in der intrinsischen Strahlenempfindlichkeit auch 
bei Tumoren ähnlicher Herkunft oder mit ähnlichen histologischen Eigenschaften. Die 
Vorhersage der Strahlenempfindlichkeit von Tumoren könnte die Tumorheilungsraten 
verbessern und eine individuelle Behandlung ermöglichen. Die Bestimmung der 
Strahlenantwort mittels DNA-Doppelstrangbruch (DSB) Biomarkern zeigt ein 
vielversprechendes Potential für die Vorhersage der intrinsischen Strahlenempfindlichkeit. 
Histon H2AX, eine Histon-Variante der Histon H2A Familie, wird bei DNA-DSB-Induktion rasch 
phosphoryliert, was zu gamma H2AX (γH2AX) führt. Gamma H2AX akkumuliert an DNA-DSB-
Stellen und rekrutiert anschließend DNA-Schadensreparaturmoleküle. Die Bildung von γH2AX 
wird durch einen immunhistologisch basierten Ansatz sichtbar gemacht und als Foci 
mikroskopisch nachgewiesen. Gamma H2AX Foci repräsentieren DNA-Doppelstrangbrüche, 
während residuale γH2AX Foci (detektierbare Foci 24 h nach Bestrahlung) als nicht reparierte 
Schäden betrachtet werden können. In früheren Studien zeigte der γH2AX Foci Assay ein 
hohes Potenzial als prädiktive Methode für die Strahlenempfindlichkeit. Diese Arbeit zielt 
darauf ab, den ex vivo γH2AX Foci Assay weiter zu entwickeln und zu optimieren, wodurch 
die klinische Anwendbarkeit des Assays verbessert wird.  
Im Rahmen dieser Arbeit wurden Experimente mit humanen Kopf-Hals-Plattenepithelkarzinom 
(hHNSCC) Xenograft Modellen durchgeführt. Für ex vivo Untersuchungen wurden hHNSCC 
Tumoren auf dem Hinterlauf von Nacktmäusen transplantiert, bei ausreichender Größe 
entnommen und in mehrere Stücke geschnitten oder direkt biopsiert. Die Tumorbiopsien 
wurden in Zellkulturmedium für 10 h oder 24 h reoxygeniert, gefolgt von einer Bestrahlung mit 
0 - 8 Gy. Anschließend wurden die Tumorbiopsien 24 h nach Bestrahlung fixiert und in Paraffin 
eingebettet. Für Untersuchungen des γH2AX Foci Assays unter in vivo-Bedingungen wurden 
tumortragenden Mäuse mit 0 - 8 Gy lokal bestrahlt. Die Tumore wurden 24 h nach der 
Bestrahlung exzidiert, fixiert und in Paraffin eingebettet. Die manuelle Quantifizierung von 
γH2AX Foci wurde ausschließlich im perfundierten Bereich durchgeführt. Die Diskriminierung 
zwischen oxischen und hypoxischen Regionen wurde durch Färbung mit Pimonidazol 
(Hypoxie-Marker) und BrdU (Proliferationsmarker) bestimmt. Die Foci-Anzahl wurde korrigiert, 
normalisiert und statistisch durch ein lineares gemischtes Modell (LMEM), ein lineares 
Regressionsmodell oder die Analyse der Kovarianz analysiert.  
Um die Tumorheterogenität im ex vivo γH2AX Foci Assay zu untersuchen, wurden vier 
gleichbehandelte Tumorproben pro Gruppe, d. h. unbestrahlt und ex vivo mit 4 Gy bestrahlt, 
auf γH2AX Foci analysiert. Es wurde eine ausgeprägte intratumorale Heterogenität der γH2AX 
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Foci bei einer geringen intertumoralen Heterogenität gefunden. Zwischen den 
Reoxygenierungszeiten von 10 h oder 24 h wurde kein signifikanter Unterschied in der 
Foci-Anzahl beobachtet, wodurch die klinische Durchführbarkeit des Assays verbessert 
wurde. Der Effekt der experimentellen Ansätze wurde untersucht, indem Daten dieser Studie 
(ex vivo) und vergleichbare veröffentlichte Daten (in vivo) mit dem LMEM analysiert wurden. 
Eine strahleninduzierte Veränderung der Zellkernfläche wurde in einigen ausgewerteten 
Tumorlinien in experimentellen Ansätzen gefunden. Eine größere intra- und intertumorale 
Heterogenität wurde im ex vivo Ansatz relativ zum in vivo Ansatz gezeigt. Zusätzlich wurde 
die Strahlenantwort mit den γH2AX Foci Assay in ex vivo bestrahlten Biopsien und in 
entsprechenden in vivo bestrahlten Tumoren evaluiert. Das Ergebnis zeigte bei vier von fünf 
Tumormodellen einen vergleichbaren Anstieg der Dosis-Wirkungs-Kurven (SDRC) von 
normalisierten und korrigierten γH2AX Foci Werten. Die SDRC normalisierter Foci konnte 
Tumoren basierend auf der intrinsischen Strahlenempfindlichkeit (TCD50) in radiosensible und 
radioresistante Gruppen klassifizieren.  
Zusammenfassend konnte gezeigt werden, dass der ex vivo γH2AX Foci Assay ein 
vielversprechendes Potenzial zur Vorhersage der Strahlenempfindlichkeit in soliden Tumoren 
besitzt. Die vergleichbaren Strahlenantworten, die durch γH2AX Foci von in vivo bestrahlten 
Tumoren und den entsprechenden ex vivo bestrahlten Tumorbiopsien evaluiert wurde, 
unterstützen die klinische Anwendbarkeit des Assays. Unter Verwendung der SDRC der 
γH2AX Foci als Prädiktor der Radiosensitivität konnten resistente und empfindliche Tumore 
klassifiziert werden. Die signifikante intratumorale Heterogenität im ex vivo γH2AX Foci Assay 
legte eine begrenzte Repräsentativität einer einzelnen Biopsie für die Vorhersage der 
Radiosensitivität nahe. Darüber hinaus modulierte die Veränderung des Tumormikromilieus 
die zelluläre Adaptation und die Fähigkeit zur Reparatur von DNA-Schäden. Die Ergebnisse 
deuten darauf hin, dass eine ausreichende Anzahl von Zellen, Auswertungsregionen und 
Biopsien erforderlich sind, um eine solide Vorhersage zu erhalten. 
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Appendices 
Part A: Materials 
The materials listed below were used for the entire study including the publications and the 
manuscript  
A.1 Tumor lines 
Table A.1 Characteristics of tumor lines  
Tumor lines SKX UT-SCC-45 FaDu Cal33 UT-SCC-5 
Origin University 
Hospital 
Hamburg-
Eppendorf 
University of 
Turku, 
Finland 
ATCC, 
Rockville, 
USA 
DMSZ 
Braunschweig 
University of 
Turku, 
Finland 
Anatomic site 
of origin 
Floor of 
mouth  
Floor of 
mouth  
Hypopharyng
eal  
Tongue  Tongue 
Grading G2 n.a. G4 G2 G3 
TNM Stage T4N2M0 T3N1M0 n.a. n.a. T1N1M0 
P53 status mutated n.a. mutated mutated mutated 
HPV status negative positive negative negative negative 
TCD50 (30fx/ 6wk) 
[95%CI] 
11.76 
[11.3; 12.2]a,b 
45.4 
[38; 52] 
85.2 
[77; 96] 
105.2 
[90; 141] 
117.2 
[103; 140] 
TCD50 (SDambient) 
[95%CI] 
14.9 
[10.9; 18.9] 
23.3 
[15; 29] 
38.9 
[35; 44] 
38.1 
[32; 45] 
42.7 
[38; 48] 
a: Standard deviation, b:TCD50 fx values after irradiation with 12 fractions within 6 weeks,  
n.a.: not available 
TCD50 values were taken from: Yaromina et al., 2010; Menegakis et al., 2011; Koch et al., 2013 
A.2 Chemicals and Materials 
Table A.2 Chemicals  
Chemicals Manufacturer  
Faramount, Mounting Medium, Aqueous Agilent Technologies Deutschland 
GmbH, Hamburg, Germany Fluoromount, Mounting Medium, Aqueous 
Xylazine Rompun® Bayer Healthcare GmbH, Leverkusen, 
Germany 
Ethanol 96.3%, denatured Berkel AHK, Berlin, Germany 
Dulbecco's Modified Eagle Medium (DMEM) Biochrom AG, Berlin, Germany 
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Chemicals Manufacturer  
Non-essential amino acids Biochrom AG, Berlin, Germany 
Penicillin/Streptomycin  
HEPES Buffer  
Sodium Pyruvate  
Cutasept F Bode Chemie GmbH, Hamburg, 
Germany 
Sodium chloride, >99.5%, p.a. Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
Ketamine 500 Curamed® Curamed Pharma GmbH, Karlsruhe, 
Germany 
Potassium chloride  Fluka Feinchemikalien GmbH, Neu-Ulm, 
Germany 
Saline solution Fresenius Kabi AG, Bad Homburg, 
Germany 
DAPI(4′,6-diamidino-2-phenylindole), 1mmol/l Invitrogen, Karlsruhe, Germany 
Disodium hydrogen phosphate Merck KGaA, Darmstadt, Germany 
Potassium dihydrogen phosphate  
Citric acid monohydrate  
Hematoxylin  
Pimonidazole (HP3-1000, Omni-Kit) Natural Pharmacia International Inc., 
Burlington, MA, USA 
Tarivid® (Ofloxacin) Sanofi-Aventis Deutschland GmbH, 
Frankfurt am Main, Germany 
Bromodeoxyuridine (BrdU) SERVA electrophoresis GmbH, 
Heidelberg, Germany 
Agarose Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany Fetal Calf Serum (FCS) 
Xylene VWR International GmbH, Darmstadt, 
Germany Formaldehyde (4 %) 
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Table A.3 Kits 
Kits Manufacturer 
Animal Research Kit (ARKTM) Agilent Technologies Deutschland 
GmbH, Hamburg, Germany 
Tyramide Signal Amplification (TSA) Kits #2 
(Alexa 488)  
Life Technologies GmbH, Darmstadt, 
Germany 
Table A.4 Materials 
Materials Manufacturer 
Fine needle biopsies, BioPince 18G, 1.3 mm Argon Medical Devices Inc., Frisco, TX, 
USA 
Embedding cassettes, for biopsies  Engelbrecht Medizin- und Labortechnik  
GmbH, Edermünde, Germany Coverslips No. 1, 24×60 mm, 24×32 mm 
Microscope slides, StarFrost®, Advanced 
Adhesive 
Falcon™ conical centrifuge tubes 50 ml, 15ml Greiner Bio-One International GmbH,  
Frickenhausen, Germany 
Nunc™ Petri dishes 35 mm Thermo Fisher Scientific GmbH, 
Dreieich, Germany 
Table A.5 Antibodies 
Antibodies Manufacturer Concentration 
Anti-Bromodeoxyuridine 
(Clone Bu20a), mouse, monoclonal  
Agilent Technologies 
Deutschland GmbH, Hamburg, 
Germany 
1:50 
Anti-phospho-Histone H2A.X (Ser139) 
(JBW301), mouse, monoclonal 
Merck Chemicals GmbH, 
Schwalbach am Taunus, 
Germany 
1:1000 
Anti-Pimonidazole, mouse, 
monoclonal 
Natural Pharmacia International 
Inc., Burlington, MA, USA 
1:50 
A.3 Devices and Software 
Table A.6 Devices  
Devices Manufacturer 
Microscope AxioImager M1  Carl Zeiss Jena GmbH, Jena, Germany 
Axiocam MRc (Digital color camera) 
AxioCam MRm (Monochrome camera) 
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Devices Manufacturer 
Vortex Mixer VF2 IKA-Werke GmbH & Co. KG, Staufen, 
Germany 
Dosimeter UNIDOS Universal Dosemeter 
11767 
PTW Freiburg GmbH, Freiburg, 
Germany 
Biological safety workbench Herasafe™ Thermo Fisher Scientific GmbH, 
Dreieich, Germany Spin Tissue Processor Microm STP120 
CO2 Incubator Heracell™ 
Rotary Microtome Microm 766 
Yxlon Y.TU320-D03 X-Ray tube Yxlon International GmbH Hamburg, 
Germany 
Laboratory balance, BP221S Sartorius AG, Göttingen, Germany 
Laboratory balance, CPA225D 
Table A.7 Software 
Software Developer 
Zen 2.6 Carl Zeiss Jena GmbH, Jena, Germany 
AxioVision SE64 Rel. 4.9.1  
GraphPad Prism 6 GraphPad Software Inc., San Diego, CA, 
USA 
SPSS 23 IBM Deutschland GmbH, Ehningen, 
Germany 
OriginPro8G OriginLab Corp., Northampton, MA, USA 
Rstudio RStudio, Inc, Boston, MA, USA 
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Part B: Supplementary materials 
B.1 Supplementary materials of publication I 
 
 
 
Suppl. Fig 1. Exemplary scattered- and box plots of γH2AX foci in four specimens of an 
individual (A) SKX, (B) FaDu and (C) UT-SCC-5 tumor. Foci were corrected with a tumor 
specific mean nucleus area (Nfoci1) or a global tumor model specific mean nucleus area 
(Nfoci2). Foci normalization was carried out with tumor specific cfoci0. Comparison of the 
correction approaches was performed by paired-sample sign test with a significance level of 
0.05. (*** p ˂ 0.0001) 
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Suppl. Fig. 2 The reoxygenation time had no statistical significance on the distribution of 
Nfoci1 in SKX, FaDu and UT-SCC-5 determined by the linear mixed-effects model.
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B.2 Supplementary materials of publication II 
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B.3 Supplementary materials of manuscript 
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